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Zusammenfassung I 
Zusammenfassung 
Burnet und Thomas postulierten 1957 die Hypothese, dass Lymphozyten neu entstehende 
Tumore erkennen und eliminieren können. Erreichen Tumore jedoch eine kritische Masse, 
entziehen sich diese den verschiedenen Kontrollmechanismen des Immunsystems. Ein 
möglicher Weg zur immunologischen Tumorkontrolle ist die Herstellung von T-Zellen, in die 
ein chimärer Antigenrezeptor (CAR) eingebaut wird, der Antigene auf Tumorzellen erkennt. 
Somit ist es möglich, eine große Anzahl Tumor-spezifischer T-Zellen ex vivo herzustellen. 
CARs sind Fusionsproteine, die aus einem Einzelketten-Antikörper-Fragment 
(Bindedomäne) und einer intrazellulären Signaldomäne bestehen. CARs der ersten 
Generation besitzen als intrazelluläre Signaldomäne CD3, wohingegen CARs der zweiten 
Generation über eine zusätzliche CD28 kostimulatorische Domäne verfügen. Das 
Einzelketten-Antikörper-Fragment der Bindedomäne erkennt ein Tumor-assoziiertes Antigen, 
woraufhin die T-Zellen spezifisch Tumorzellen erkennen. NY-ESO-1 ist ein Tumor-
assoziiertes Antigen, das in einer Vielzahl unterschiedlichster Krebsarten exprimiert wird. In 
einem früheren Projekt wurde ein Antikörpermolekül generiert, das das immundominante 
NY-ESO-1 Peptid 157-165 im Kontext des HLA-A*02:01 Moleküls erkennt.  
Um eine Erkennung des NY-ESO-1 Proteins durch autologe CD8+ Zellen zu ermöglichen, 
wurden in dieser Studie CARs generiert, deren Einzelketten-Antikörper-Fragment das NY-
ESO-1 Peptid 157-165 im Kontext des HLA-A*02:01 Moleküls bindet. Entsprechend 
modifizierte T-Zellen lysierten NY-ESO-1157-165/HLA-A*02:01 positive Zielzellen und 
sezernierten IFN in spezifischer Weise. T-Zellen mit Expression eines 2. Generation CARs 
zeigten sowohl höhere zytolytische Aktivität wie auch Zytokinsekretion im Vergleich zu T-
Zellen mit Erstgenerationskontrukt. Phänotypische Analysen CAR tragender T-Zellen zeigten 
in 40 % der T-Zellen einen ‚Effector-Memory‘-Phänotyp. Interessanterweise wurde auch eine 
‚Central-Memory‘-Population in 3 – 8 % CAR positiver T-Zellen gefunden. Aufgrund der 
CCR7 Expression wurden Effektor- sowie Gedächtniszellen separiert. Nach Antigen-
spezifischer Aktivierung zeigten CCR7+ Gedächtniszellen eine spezifische 
Herunterregulation ihres CCR7 Rezeptors, welches eine Differenzierung zu Effektorzellen 
andeutete. Weiterhin sezernierten CCR7 positive Gedächtniszellen vor allem IL-2, ein 
Zytokin, welches für ‚Central-Memory‘-Zellen charakteristisch ist. CAR tragende T-Zellen 
verhinderten die Entstehung eines Multiplen Myeloms in einem Xenograft Modell. Allerdings 
verursachten die injizierten T-Zellen nach 30 Tagen eine Xeno-Graft-versus-Host Reaktion. 
Diese Ergebnisse stellen eine Grundlage für eine mögliche klinische Anwendung CAR 
tragender T-Zellen in der Therapie des Multiplen Myeloms dar. CAR tragende T-Zellen, 
welche den CCR7 Rezeptor exprimieren, sind von besonderem Interesse für die 
II Zusammenfassung 
Weiterentwicklung der adoptiven T-Zelltherapie, um deren Gedächtnisfunktion für eine 
Langzeitprotektion gegen rezidivierende Tumore zu nutzen. 
 
Abstract III 
Abstract 
In 1957, Burnet and Thomas hypothesized the concept of cancer immune surveillance which 
proposes that lymphocytes recognize newly developing transformed cells and eradicate 
them. However, tumors that are able to form a critical mass escape the various mechanisms 
of the immune system. One promising approach to immunological tumor control is to 
genetically modify T cells with a chimeric antigen receptor (CAR) that recognizes antigens on 
tumor cells. Consequently, it is possible to generate large scale tumor-specific T cell 
populations ex vivo. CARs are single fusion-proteins that contain a single chain fragment 
(scFv) binding and an intracellular signaling domain. T cells harboring a CAR are called re-
directed T cells. First generation CARs consist of an intracellular CD3 signaling domain only 
whereas second generation constructs combine the co-stimulatory CD28 domain and the 
CD3 signaling domain. The binding domain of CARs recognizes a tumor associated antigen 
which re-directs T cells towards tumor cells. NY-ESO-1 is a tumor associated antigen 
expressed on a wide variety of malignant neoplasms. In the past, a Fab fragment was 
generated which recognizes the immuno-dominant peptide 157-165 of NY-ESO-1 complexed 
in the binding groove of the HLA-A*02:01 molecule. 
In this study, chimeric antigen receptors (CARs) were generated consisting of a single chain 
antibody fragment recognizing the immuno-dominant NY-ESO-1 peptide 157-165 in the 
context of HLA-A*02:01 linked to the CD3 or CD28-CD3 activation domain. These re-
directed T cells lysed specifically NY-ESO-1157-165/HLA-A*02:01 positive cells and secreted 
IFN. T cells expressing second generation constructs were superior to T cells harboring first 
generation constructs in cytolysis as well as cytokine release. Phenotypical analysis of re-
directed T cells revealed an effector-memory phenotype in 40 % of T cells. Interestingly, a 
subpopulation of central memory T cells was identified comprising 3 – 8 % of the re-directed 
T cell population. Based on CCR7 cell sorting, effector and memory CAR positive T cells 
were separated. CCR7+ memory cells demonstrated after antigen specific re-stimulation 
down-regulation of CCR7 as sign of differentiation towards effector cells and increased 
secretion of IL-2, the signature cytokine of central memory T cells. Furthermore, CAR re-
directed T cells were able to prevent tumor outgrowth of multiple myeloma in a xenograft 
model but also triggered xeno-GvHD 30 days post injection. 
The results are a rational for the potential clinical use of NY-ESO-1 re-directed T cells for 
therapy of multiple myeloma. CCR7+ re-directed T cells are of special interest for further 
development of adoptive T cell therapy to not only resolve existing primary tumors but also to 
keep residual or dormant tumor cells under control. 
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Introduction 1 
1 Introduction 
1.1 The concept of immune surveillance 
Proliferation and differentiation of normal cells are governed by many control and 
feedback mechanisms. However, malignant transformation of cells overcomes these 
mechanisms and establishes a progressive neoplastic state. Hanahan and Weinberg 
published in 2000 six common traits, also referred to as hallmarks of cancer that are the 
underlying principles of the onset and progression of oncogenesis. Cancer cells are self-
sufficient in growth signals, insensitive to growth inhibitory signals, resistant to apoptosis, 
have a limitless replication potential, are able to sustain angiogenesis and invade tissues 
as well as develop metastasis (Hanahan & Weinberg, 2000). In 2004, Schreiber and 
colleagues proposed the evasion of immune surveillance as the possible seventh hallmark 
of cancer (Dunn et al., 2004b; Smyth et al., 2006). This concept has gained more and 
more acceptance and Hanahan and Weinberg include it as new hallmark in their updated 
version (Hanahan and Weinberg, 2011). 
The concept of immune surveillance conveys that tissues and cells are constantly 
monitored by the immune system. Thereby, immune cells recognize and eradicate arising 
tumor cells which prevent formation of a vast majority of newly developing malignant cells 
(Dunn et al., 2004a). However, malignant cells that are able to form a critical mass escape 
the various mechanisms of the immune system by either circumventing detection or 
blocking the cytolytic response (Dunn et al., 2004a).  
The importance of immunological surveillance to control cancer development was shown 
in various pre-clinical and clinical studies. Immunocompromised individuals are more 
prone to develop certain cancers like Kaposi sarcoma and Hodgkin´s lymphoma. But 
many of these cancer types are virus-induced (Vajdic and van Leeuwen, 2009). In recent 
years, increasing evidence is found that the immune system also plays a decisive role in 
tumor formation and progression in non-virus-induced cancers like multiple myeloma and 
colorectal cancer (Vajdic and van Leeuwen, 2009). In vivo studies showed that genetically 
engineered mice lacking parts of the innate (natural killer (NK) cells) and/or the adaptive 
immune system (CD8
+
 cytotoxic T lymphocytes (CTLs), CD4
+
 Th1 helper T cells) have a 
higher incidence of cancer occurrence and/or a more rapid tumor growth (Teng et al., 
2008; Kim et al., 2007). Furthermore, tumors which arise from immunodeficient mice and 
subsequently are transplanted to syngeneic hosts are unable to develop secondary 
tumors. Whereas, cancer cells harvested from immunocompetent mice give rise to 
secondary tumors in both immunocompromised and immunocompetent hosts (Teng et al., 
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2008; Kim et al., 2007). These data further substantiate both the potential host-protective 
and tumor-editing functions of the immune system during tumor development (Dunn et al., 
2004a and 2004b, Dunn et al., 2002). Additionally, clinical studies substantiate the 
concept of immune surveillance in some forms of human tumors like gastrointestinal, 
ovarian and head and neck cancers (Bindea et al., 2010; Ferrone and Dranoff, 2010; 
Nelson, 2008). Pagès et al. and Nelson demonstrated that patients with infiltrations of 
CTLs and NK cells in colorectal and ovarian cancerous lesions have a better prognosis 
compared to patients lacking these cells (Pagès et al., 2010; Nelson, 2008). Furthermore, 
Strauss and Thomas showed in 2010 that immunocompromised organ recipients develop 
donor-derived cancers which are not detectable in the donors suggesting that the 
functional immune system of the organ donor is controlling tumor development. 
1.2 Tumor associated antigens (TAAs) 
Cancer cells need to be recognized by CTLs to be lysed. Thereby, studies revealed that 
malignant cells express so-called tumor associated antigens (TAAs) which can be used by 
the immune system to recognize malignant cells. 
Technological advances in the field of immunology have led to a more precise 
understanding and definition of TAAs. Molecules falling into the category of tumor 
antigens must be produced by tumor cells and recognized by antibodies and/or immune 
cells. Thereby, some tumor antigens are exclusively tumor specific others are also 
expressed in normal tissues.  
1.2.1 General categorization of TAAs 
The above mentioned definition of TAAs and their better molecular characterization have 
allowed a categorization of tumor antigens into eight groups which are shown in table 1-1 
(De Smet et al., 1997; Wang & Rosenberg, 1999; Renkvist et al., 2001; Thompson et al., 
2000).  
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Category of 
tumor 
antigen 
Description Example Antigen 
(Cancer Histology) 
Reference 
Oncofetal Typically only expressed 
in fetal tissues and in 
somatic tumor cells 
CEA (colorectal 
carcinoma) 
Immature laminin 
receptor (renal cell 
carcinoma) 
Shievely and 
Beatty, 1985 
Zelle-Rieser et 
al., 2001 
Oncoviral Encoded by tumorigenic 
transforming viruses 
HPV E6, E7 (cervical 
carcinoma) 
Breitburd and 
Coursaget, 
1999 
Overexpress
ed/ 
accumulated 
Expressed in normal 
tissue and in neoplasia, in 
the latter highly elevated 
Her2/neu (breast 
carcinoma, multiple) 
SAP-1 (colorectal 
carcinoma) 
Bernard et al., 
2002 
Seo et al., 
1997 
Cancer-testis Expressed in healthy testis 
and placenta and in tumor 
cells 
NY-ESO-1 (multiple) 
 
MAGE-1 (multiple) 
Chen et al., 
1997a 
Chomez et al., 
2001 
Lineage-
restricted 
Expressed by a single 
tissue histotype 
Melan-A/MART-1 
(Melanoma) 
Prostate Specific 
Antigen (Prostate 
carcinoma) 
Kawakami et 
al., 1994 
Alexander et 
al., 1998 
Mutated Genetic mutation or 
alteration in transcription 
in cancer cells lead to their 
expression  
ß-catenin (Melanoma, 
Prostate carcinoma, 
hepatocellular 
carcinoma) 
BRCA1/2 (Breast, 
ovarian carcinoma) 
Robbins et al., 
1996 
 
Welcsh and 
King, 2001 
Posttrans- 
lationally 
altered 
Alterations in 
glycosylation, etc. that are 
tumor associated 
MUC1 (ductal 
carcinoma, renal cell 
carcinoma) 
Jerome et al., 
1991 
Idiotypic  Tumor cells expressing a 
specific clonotype due to 
highly polymorphic genes  
Ig, TCR (B, T cell 
leukemia, lymphoma, 
myeloma) 
Bhattacharya-
Chatterjee and 
Foon, 1998 
Table 1-1: Categorization of tumor associated antigens. 
1.2.2 The cancer testis antigen NY-ESO-1 
Since defining the different groups of TAAs progress has been made to assess their value 
as possible targets for cancer immunotherapy. In 2009, Cheever et al. started a National 
Cancer Institute pilot project to prioritize cancer antigens in regards to their potential to 
elicit an immune response. They compared 75 TAAs ranking them by the following 
criteria: (1) therapeutic function, (2) immunogenicity, (3) role of the antigen in 
oncogenicity, (4) specificity, (5) expression level and percent of antigen-positive cells, (6) 
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stem cell expression, (7) number of patients with antigen-positive cancers, (8) number of 
antigenic epitopes and (9) cellular location of antigen expression (Cheever et al., 2009). 
NY-ESO-1 from the group of the cancer testis antigens is listed as number 10.  
In 1997, Chen et al. discovered the cancer testis antigen NY-ESO-1 using serum from a 
patient with squamous cell carcinoma of the oesophagus (Chen et al., 1997a; Chen et al., 
1997b). The serum was screened against prokaryotically expressed cDNA libraries 
prepared from tumor specimens for detection of tumor antigens that triggered a humoral 
immune response with the help of a technology called SEREX (serological analysis of 
recombinant cDNA expression libraries).  
NY-ESO-1 is a protein of 180 amino acids (aa) and a molecular mass of 18 kDa. It is pre-
dominantly expressed in the cytoplasm but can be found in the nucleus of some 
spermatogonia (Jungbluth et al., 2001b). NY-ESO-1 as a potential candidate for 
immunotherapy is especially attractive because its expression is limited to tumor cells and 
immune-privileged regions as spermatogonia, oogonia and placenta (Simpson et al., 
2005; Jungbluth et al., 2001b) (figure 1-1).  
 
Figure 1-1: Immunohistochemical staining of tissue for NY-ESO-1 expression. 
(A) Normal testis shows intratubular staining of spermatogenic cells (adapted from Gjerstorff et al., 2006). (B) 
Malignant melanoma tissue shows high NY-ESO-1 expression levels (adapted from Jungbluth et al., 2001b). 
The function of the NY-ESO-1 protein is not known. There is no rodent homologue and no 
NY-ESO-1 transgenic animal studies are published (Nicholaou et al., 2006). NY-ESO-1 is 
expressed in germ cells and trophoblasts but its rapid decline during differentiation 
processes suggests a role in germ cell self-renewal or differentiation (Jungbluth et al., 
2001b; Satie et al., 2002; Takahashi et al., 1995). NY-ESO-1 is expressed in a wide 
variety of cancer types. Highest frequencies of NY-ESO-1 protein expression are reported 
for neuroblastoma (82 %; Rodolfo et al., 2003), synovial sarcoma (80 %; Jungbluth et al., 
2001a) melanoma (46 %; Barrow et al., 2006) and epithelial ovarian cancer (43%; Odunsi 
et al., 2003) as detected by immunohistochemistry. 60 % of multiple myelomas after 
relapse express NY-ESO-1 mRNA as measured with RT-PCR (van Rhee et al., 2005). 
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Furthermore, accumulation of NY-ESO-1 expression in multiple myeloma has been shown 
in advanced stages of the disease (Dhodapkar et al., 2003).  
NY-ESO-1 is an intracellular antigen. Therefore, it needs to be intracellular processed 
before it can be presented on the cell surface to the immune system, especially to T cells. 
Indeed, many T cell responses specific to NY-ESO-1 peptide loaded HLA molecules have 
been found in cancer patients (Jäger et al., 1998; Gnatjic et al., 2002). Thereby, a wide 
variety of immunogenic peptides were found complexed to HLA molecules which are 
recognized by CD4
+
 and CD8
+
 T cells. One immunogenic domain of cytotoxic T 
lymphocytes was discovered in the C-terminal area of the NY-ESO-1 protein 
compromising of aa 157-165. Furthermore, clinical trials show that CTLs are able to lyse 
NY-ESO-1157-165/HLA-A*02:01 expressing tumor cells after vaccination with NY-ESO-1157-
165 peptide (Dutoit et al., 2002).  
1.3 Human leukocyte antigen (HLA) system 
The genes of the HLA system, the major histocompatibility complex in humans are located 
on chromosome six (Klein, 1986; Klein, 1998; Forbes, 1999). They code for cell surface 
molecules that present antigenic peptides to T cells and are divided in two classes, class I 
and class II. The two different classes differ in their structure and function. 
Class II molecules are loaded with peptides (at least 13 aa long) from extracellular 
proteins that previously have been engulfed and processed by an antigen presenting cell 
(APC). The APC, namely dendritic cells, B cells and macrophages presents the 
peptide/HLA class II complex to CD4
+
 T cells, whose main function is to activate/regulate 
other cells of the immune system. 
Class I molecules are expressed on all nucleated cells and on platelets and are loaded 
with peptides from degraded intracellular proteins. They consist of two non-covalently 
linked polypeptide chains. The HLA coded -chain and the 2- microglobulin subunit are 
encoded on chromosome 15. The classical genes are HLA-A, B and C. HLA-A*02 is 
commonly expressed but the allelic variant A*02:01 is the main variant in Northern Asia 
and Northern America. 
1.3.1 Structure of HLA class I molecules 
The HLA class I molecule consists of two noncovalently linked polypeptide chains, the 
larger  chain and the smaller 2-microglobulin. The whole protein consists of four 
domains; three are formed by the  chain and one by 2-microglobulin. Only the  chain 
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spans the membrane (Janeway et al., 2001). Proper folding of the 1 and the 2 domains 
leads to formation of a cleft enabling peptide binding (figure 1-2).  
 
 
 
 
 
 
Figure 1-2: The structure of an 
HLA class I molecule.  
Panel A shows a ribbon diagram of 
the HLA-A2 molecule. Panel B 
depicts a schematic representation 
of an HLA class I molecule. 
Adapted from Janeway et al., 2001. 
1.3.2 HLA class I synthesis and peptide loading 
Developing an adaptive immune response requires the recognition of an antigen by a 
corresponding antigen-specific receptor on T cells or B cells. T cells recognize a peptide 
residing in the binding groove of a HLA-molecule which is presented on the cell surface as 
a complex. Generation of peptide-HLA-class I complexes is a multi-step process. Peptides 
loaded on HLA class I molecules can either emerge from self-proteins or from products of 
viruses or intracellular pathogens. Most HLA class I-associated peptides are 8-11 aa long 
with a typical length of 9 residues (Falk et al., 1991).  
Proteasomes which are abundant and ubiquitous multi-catalytic protease complexes are 
responsible for the degradation of most proteins and the generation of peptides (Rock et 
al., 1994). These peptides are between 4 and 20 amino acids in length (Kisselev et al., 
1991) which implies that not all peptides can be presented by HLA class I molecules. 
Extended peptides are further processed by aminopeptidases in the cytoplasm (Reits et 
al., 2003) or in the endoplasmic reticulum (ER) (Serwold et al., 2002; Saric et al., 2002). 
Transport of the peptides from the cytoplasm into the ER is mediated by transporter for 
antigen processing (TAP) (Neefjes et al., 1993). TAP binds to the generated peptides and 
hydrolyzes one ATP molecule to open its pore for peptide translocations from the cytosol 
to the lumen of the ER (van Endert et al., 2002) where HLA class I molecules are 
synthesized. The synthesis and assembly of HLA class I molecules is a complex process 
in which peptide binding plays a key role. On the cytosolic surface of the ER ribosomes 
synthesize both poly-peptide chains (α-chain and ß2-microglobulin) of the HLA molecule in 
a separate step. Newly synthesized HLA class I -chains bind to the chaperon calnexin. 
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Binding of 2-microglobulin to the -chain leads to dissociation of calnexin from the :2-
microglobulin heterodimer. Subsequently, the heterodimer binds to the HLA-class I 
loading complex, which consists of the molecular chaperones tapasin, calreticulin, Erp 60 
(Ortmann et al., 1997) and the TAP complex itself. Tapasin connects the nascent HLA-
class I molecule with the TAP transporter for arriving peptides from the cytosol. Stable 
HLA class I-peptide complexes pass through the Golgi-complex into exocytotic vesicles to 
the cell surface. These complexes are presented to CD8
+
 T cells (figure 1-3).  
 
 
 
 
 
Figure 1-3: HLA class I antigen 
presentation. 
Proteins are degraded to small peptides 
by the proteasome. The TAP transporter 
introduces peptides into the ER where 
they are loaded onto nascent HLA class I 
molecules. The stable peptide/HLA-
complex is transported to the cell surface 
to be presented to T cells. Adapted from 
Yewdell et al., 2003. 
1.4 T cell activation 
The immune system is a complex network of specialized cells and tissues which are able 
to distinguish self from foreign. Generally, the immune system can be divided in two arms, 
the innate and the adaptive immune system which is characterized by its ability to 
recognize already encountered pathogens more efficiently and creates immunological 
memory. The arm of the adaptive immune response can further be divided in humoral and 
cellular response, where B cells and T cells are key players, respectively. In general, T 
cells are comprised of two groups, one regulates the overall complex network of an 
immune response (CD4
+
 T cells) and the other is directly cytotoxic and destroys infected 
cells (CD8
+
 T cells). 
Activation of naïve T cells is dependent on an APC type of the innate immune system, 
namely dendritic cells (DCs) (Jung et al., 2002; Steinman and Dhodapkar, 2001). 
Immature DCs capture antigens at the site of infection, process it, subsequently become 
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activated and travel downstream to the lymph node which drains the infected site. DCs 
present the processed protein as small peptide fragments complexed to HLA molecules at 
T cell zones of lymphoid organs to T cells. Naïve T cells continuously migrate from the 
bloodstream to lymphoid organs where they sample many APCs. When a TCR of a naïve 
T cell binds to the peptide/HLA complex presented by activated DCs (lock-and-key 
principle) it stops to migrate and gets activated. The activation of the naïve T cell is at 
least dependent on three signals: (1) recognition of the antigen through the T cell receptor 
(TCR); (2) co-stimulation of the T cell through engagement of CD28, CD40, 4-1BB, CD27, 
ICOS and OX40 and (3) cytokine release such as IL-2 and IFN (Mescher et al., 2006; 
Thompson et al., 2006; Xiao et al., 2009). Naïve T cells that receive these three signals 
will undergo activation, expansion and generate a large antigen-specific effector T cell 
population.  
Signal 1 is provided by the APC expressing the cognate peptide/HLA complex which is 
recognized by the T cell intrinsic TCR and the binding of CD8 or CD4 co-receptor to 
the HLA molecule. Every T cell carries around 30 000 TCRs on its cell membrane which 
have all the same specificity. Each TCR consists of two polypeptide chains, the TCR  
and TCR  chain. Each polypeptide chain compromises a variable and a constant domain, 
is anchored via a transmembrane domain and ends in a short cytoplasmic tail. The TCR  
and TCR  chains are linked via a disulfide bond. The TCR alone is not equipped to 
transfer the extracellular signal of antigen recognition into the cell. Therefore, each TCR is 
co-expressed with a non-covalently associated CD3 complex consisting of four 
polypeptide chains (two  chains, one  and one  chain) as well as a disulfide-linked 
homodimer of the  chain (figure 1-4). These signaling chains are not only necessary for 
cell surface expression of the TCR but also transport the extracellular signal over the 
plasma membrane into the cytoplasm. Every CD3 polypeptide chain contains one ITAM 
motif, every  chain three. Phosphorylation of the ITAM motifs is the first intracellular 
signaling which occurs and leads to further downstream events.  
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Figure 1-4: Schematic representation of a TCR.  
The heterodimeric TCR is co-expressed with the non-covalently attached 
CD3 complex (chains and two  chains). Adapted from Dotti et al., 
2009. 
The second signal originates from APCs which express co-stimulatory molecules on their 
cell surface. Binding of the peptide/HLA complex in the absence of co-stimulation renders 
T cells anergic or apoptotic. The best characterized co-stimulatory molecule is CD28 on T 
cells which is engaged by B7-1 and B7-2 molecules on activated APCs. Binding of CD28 
to B7 after interaction of the TCR with the peptide/HLA complex strengthens formation of 
membrane microdomains and thereby increases TCR proximity to CD3 complexes 
(Wülfing and Davis, 1998; Viola et al., 1999; Bromley et al., 2001; Wülfing et al., 2002). 
Receptor clustering also allows even weak TCR ligands to induce successful TCR 
signaling (Wülfing et al., 2002). After clustering of the TCR complex, the Lck tyrosine 
kinase which is associated with CD8 or CD4 co-receptors phosphorylates several 
immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3 complex. Z-
associated protein of 70 kDa (ZAP-70) is recruited to the phosphorylated ITAM residues 
and becomes activated by Lck phosphorylation. Further adaptor proteins are recruited to 
the activated TCR complex which ultimately leads to the activation of transcription factors 
through Ras-MAP kinase and calcium- and protein kinase C-mediated signaling 
pathways. Furthermore, the Lck tyrosine kinase also phosphorylates the sequence motifs 
of the CD28 intracellular domain which augments TCR signaling. Additionally, CD28 
signaling induces transcription factor NFb to bind to the IL-2 gene promoter which is not 
activated by sole TCR signaling (Chervin et al., 2009). In summary, CD28 signaling blocks 
activation of apoptotic pathways, stimulates cell metabolism and induces cytokine 
secretion. 
1.5 Memory T cells 
An antigen-specific CD8
+
 T cell response can be divided into three different phases, 
namely clonal expansion followed by a contraction phase and subsequent memory 
formation (figure 1-5 A). During the clonal expansion phase, naïve CD8
+
 T cells are 
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activated by recognizing their target on activated DCs and differentiate into effector cells 
whereby they rapidly down-regulate lymph node homing molecules like CCR7 and 
CD62L. This allows effector T cells to extravasate into peripheral tissues and reach 
infected areas (Bromley et al., 2005). Furthermore, effector T cells acquire two critical 
functions: the ability to lyse target cells and to secrete cytokines (Chowdhury and 
Lieberman, 2008). Cytotoxicity is mediated through release of perforin and granzymes 
and/or triggering of Fas. These mechanisms lead to induction of apoptosis of the target 
cell. Additionally, effector T cells secrete IFN and Tumor Necrosis Factor (TNF) after 
antigen contact, which contribute to increase the local inflammatory response (Slifka and 
Whitton, 2000). After elimination of the pathogen the antigen-specific effector T cell 
population contracts due to induction of programmed cell death, whereby 90-95 % of 
effector T cells are lost. The remaining 5-10 % gradually establish memory populations 
which can be maintained for very long time. These memory T cells undergo homeostatic 
proliferation without seeing their antigen for a long period of time depending on the 
cytokine milieu (Surh and Sprent, 2008). However, they are rapidly reactivated upon 
renewed antigen encounter resulting in gained cytolytic activity and cytokine secretion. 
Furthermore, their distribution in various tissues enables them to rapidly protect the host 
from recurrent infection. In general, memory T cells are subdivided into two main subsets: 
effector memory T cells (TEM) and central memory T cells (TCM) (Masopust et al., 2001; 
Sallusto et al., 1999). TEM are CCR7 and CD62L negative and are therefore patrolling non-
lymphoid tissues and mucosal sites and possess high cytotoxic potential to immediately 
confront the pathogen. In contrast, TCM home to secondary lymphoid organs due to CCR7 
and CD62L expression without immediate cytotoxicity but they possess superior 
expansion potential. 
 
Figure 1-5: Normal (A) and corrupted (B) memory T cell formation. 
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Panel A shows the formation of memory after an acute viral infection and panel B depicts the same scenario in 
a tumor-bearing host. In both cases, T cells are activated by their cognate antigen, undergo proliferation and 
90 % differentiate to terminally differentiated TEFF cells. The remaining 10 % of cells form a pool of TCM and 
TEM cells. In the physiological setting (A) the memory pool contributes to further protection of the host 
whereas, in the tumor-bearing host (B) memory T cells are driven in an exhausted state and are no longer 
able to control the disease. Adapted from Klebanoff et al., 2006. 
An acute infection with a viral antigen can mount an immune response, clear the 
pathogen, and produce functional memory T cells. However, in the tumor-bearing host this 
process is altered and/or blocked at different stages (Klebanoff et al., 2006). Especially, 
the generation of potent memory T cells is highly impaired as depicted in figure 1-5 B. 
Several mechanisms are identified that contribute to the impaired formation of memory. 
The induction of T regulatory cells (Tregs) by the immunosuppressive environment is shown 
to negatively impact on the numbers and functionality of memory CD8
+
 T cells 
(Kronenberg and Rudensky, 2005; Murakami et al., 2002; Suvas et al., 2003). 
Furthermore, the presence of other hematological cells, acting as so called cytokine 
‘sinks’ limits the access to homeostatic cytokines as IL-7 and IL-15 which are important for 
memory formation and maintenance (Gattinoni et al., 2005; Yang et al., 2004). Finally, 
repetitive/chronic antigen stimulation as it is the case in a tumor-bearing host might lead to 
functional exhaustion of CD8
+
 T cells and ultimately drive them into senescence 
(Klebanoff et al., 2006). 
Surface markers were defined for the memory and effector T cell subpopulations to further 
characterize the pool of CD8
+
 T cells. Phenotypical characterization of memory and 
effector T cell subsets has been limited to three or four-color analysis but recent advances 
in enhancing the resolution of higher order flow cytometry produced a more 
comprehensive survey. Figure 1-6 depicts the phenotypical changes of naïve T cells on 
their way to terminally differentiated T cells. 
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Figure 1-6: Phenotypical and functional changes of the CD8
+
 T cell compartment induced by chronic 
antigen stimulation.  
Naïve CD8
+
 T cells become terminally differentiated TEFF and finally enter the state of senescence. The 
expression levels of the phenotypic markers are described as (+++) high expression (++) intermediate 
expression and (+) low expression. Adapted from Klebanoff et al., 2006. 
 
Employing flow cytometry with five distinct memory markers, Walker et al. identified in 
disease-free melanoma patients gp100 specific memory CD8
+
 T cells (Walker et al., 
2008). Thereby, they describe early TEM (CCR7
–
CD45RA
–
CD57
–
CD27
+
CD28
+
) and late 
TEM (CCR7
–
CD45RA
–
CD57
–
CD27
+
CD28
–
) as well as TCM phenotypes (CCR7
+
CD45RA
–
CD57
–
CD27
+
CD28
+
). Furthermore, TEMRA cells, previously described by Sallusto and 
Lanzavecchia (Sallusto et al., 1999) by four-color analysis are assigned the following five-
color combination CCR7
–
CD45RA
+
CD57
–
CD27
+
CD28
+/–. This phenotype designates the 
re-expression of CD45RA on TEM cells before they acquire CD57 and concurrently lose 
their CD27 and CD28 molecules which lead to the terminal effector state (Tomiyama et 
al., 2002; Takata and Takiguchi, 2006). Walker et al. introduced a previously not 
delineated sub-phenotype which expresses CD45RA together with a central memory 
phenotype (CCR7
+
CD45RA
+
CD57
–
CD27
+
CD28
+
). Therefore, these T cells are termed 
TCMRA and are discovered to be an antigen-educated memory population as this 
phenotype is only detected after repetitive vaccination. Finally, fully differentiated effector 
T cells (CCR7
–
CD45RA
+
CD57
+
CD27
+/–CD28
–
) are also found among the tumor-antigen 
specific subpopulation.  
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1.6 Chimeric Antigen Receptor (CAR) engineered T cells 
The approach of cancer immunotherapy and, in particular, adoptive cell therapy (ACT) is 
still considered to be in its infacy. Since first reports of adoptive transfer of cytotoxic T 
cells (Kolb et al., 1990) or tumor infiltrating lymphocytes (TILs) (Rosenberg et al., 1988) 
laid the groundwork for human application of the treatment of cancer the interest in 
genetic engineering of T cells to re-direct their effector function has been greatly 
increased. The basis for genetic T cell engineering was formed by the generation of 
recombinant DNA in the 1970s and the development of efficient gene transfer methods in 
the early 1980s. There are two major approaches to re-direct effector T cell specificity, 
namely TCR- and chimeric antigen receptor (CAR) - engineering.  
1.6.1 The concept of adoptive cell therapy 
Discovering CD8
+
 CTLs which recognize presented TAA peptide/ HLA molecule-
complexes on the cell surface of tumor cells and their subsequent lysis of these cancer 
cells has given T cell based immunotherapy of cancer much impetus (Rosenberg 2001). 
The concept of ACT for cancer therapy was hypothesized after discovering tumor-specific 
and -reactive T cells in cancer patients (Rosenberg et al., 2008). Isolation, in vitro 
activation, expansion and re-infusion of tumor-specific T cells has been applied in different 
viral and non-viral related malignancies. In 1988, Rosenberg et al. demonstrated for the 
first time regression of melanoma lesions in patients by infusing tumor infiltrating 
lymphocytes (TILs). In these early studies, response rates were modest but improved with 
the addition of host preconditioning using non-myeloablative chemotherapy (Dudley et al., 
2002). Despite these promising results, this therapy is limited to a small number of 
patients since the isolation and expansion of TILs emerged to be labor-intensive, 
technically difficult and time consuming. To overcome these limitations new strategies are 
required to generate tumor-specific T cells. Thereby, genetic modification of T cells is a 
promising approach in order to generate large T cell populations which are re-directed to 
recognize tumor cells. Two major routes of re-directing effector T cell specificity evolved 
over the past years. T cells can be engineered to express exogenous  TCRs or CARs 
(Morgan et al., 2010a).  
1.6.2 TCR engineering and CAR engineering 
Although gene transfer of native  TCRs achieved some remarking results in melanoma 
patients (Morgan et al., 2006), it is affiliated with some concerns. Pairing of the 
endogenous TCR chain with the transgenic one may result in de novo receptor 
specificities which recognize autologous peptide/MHC complexes and thereby convey 
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autoimmune reactions (Cartellieri et al., 2010). Furthermore, TCRs have an inherent low 
affinity for their antigen (Corr et al., 1994) and are well known to exhibit a degree of 
promiscuity to their peptide/HLA ligands (Mason, 1998). One attempt to overcome these 
limitations resulted in replacing the variable parts of the TCR  and  chains with single 
chain fragment variable (scFv) derived from monoclonal antibodies (figure 1-7 A). This led 
to recognition of antigens in a non-HLA-restricted manner (Becker et al., 1989; Gross et 
al., 1989; Kuwana et al., 1987). The soon followed discovery of the CD3 chain being on 
its own sufficient for activation of T cells (Irving et al., 1993; Letourneur and Klausner et 
al., 1991) resulted in the cloning of the first CAR construct, where a scFv was fused to the 
CD3 chain (Eshhar et al., 1993). Eshhar et al. termed this concept the ‘T body 
approach’, nowadays these engineered chimeric receptors are termed CARs (Eshhar et 
al., 1996).  
1.6.3 Properties of chimeric antigen receptors 
In general, CARs are composed of a specific-antigen binding domain which is derived 
from a scFv antibody fragment and fused to a flexible hinge domain (from CD8 or 
immunoglobulin sequence) (Imai et al., 2004; Zhao et al., 2009) which leads via a 
transmembrane domain to the endodomain which consists of 1 to 3 cytoplasmic moieties 
(figure 1-7 B). First generation CAR constructs harbor as endodomain CD3-, CD3-,  
CD3- derived from the T cell receptor complex or high-affinity receptor FcRI (Yun et al., 
2000; Abken et al., 2003) which transmit the activation signal into the T cell thereby 
allowing it to gain effector functions and subsequently lyse target cells. Introduction of a 
co-stimulatory domain, predominantly as a CD28 ITAM fusion protein (Finney et al., 1998; 
Krause et al., 1998) led to the generation of second generation CAR constructs. In 
contrast to the physiological activation of TCR and CD28 receptors, CD28-CD3 CARs 
function as one fusion protein and no recruitment of CD28 into the immunological synapse 
is necessary to get sufficient T cell activation. Therefore, CD28 co-signaling is provided 
without the engagement of B7.1 molecules. Third generation constructs comprise one 
further co-stimulatory moiety primarily from the B7 family (ICOS) or the tumor necrosis 
factor receptor superfamily (4-1BB, OX40) (Croft 2009; Greenwald et al., 2005). In most 
cases, the antigen binding domain recognizes a cell surface protein in a HLA-unrestricted 
manner. To access intracellular antigens scFv were selected which bind in a TCR manner 
a peptide complexed in a HLA molecule (Stewart-Jones et al. 2009, Willemsen et al., 
2005). 
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Figure 1-7: Schematic representation of an antibody (A) and of different CAR constructs (B).  
(A) The scFv consists of variable heavy chain (VH) and variable light chain (VL) domains, whereas the Fab 
fragment yields additionally two constant domains (constant light chain (CL) and constant heavy chain 1 
(CH1)). (B) First generation CARs harbor only the signaling domain , second generation CARs an 
additionally co-stimulatory moiety and third generation constructs yield two additionally co-stimulatory 
domains. Adapted from Dotti et al., 2003. 
1.6.4 Methods to express CARs in T cells 
Several methods have been used to express chimeric receptors in T cells and are still 
under evaluation. Most studies use viral vectors that integrate the CAR sequence in the 
host DNA which is possible due to the high proliferative potential of T cells (Dotti et al., 
2009). Thereby, gamma-retroviral vectors have already been tested in several clinical 
trials (Rosenberg et al., 1990; Bordignon et al., 1995; Heslop et al., 1996, Bonini et al., 
1997) and have been proven as a reliable and safe method to re-direct mature T cells. 
Limitations of retroviral gene transfer include DNA insertion only in dividing cells (Miller et 
al., 1990), vectors hold limited cargo (Hu and Pathak et al., 2000), DNA insertion in the 
genome might cause insertional mutagenesis (Hacein-Bey-Abina et al., 2008) and vectors 
are expensive to produce for clinical applications. Furthermore, expression of the CAR 
can decline over time, but after T cell activation it increases (Pule et al., 2008). 
Nonetheless, in 20 years of treating patients with retrovirally transduced T cells no 
adverse effect related to insertional mutagenesis was reported (Bonini et al., 2003; 
Brenner and Heslop, 2003). Additionally, Montini et al. showed that retroviral gene-
modified T cells do not undergo malignant transformation in RAG1-deficient mice (Montini 
et al., 2006). A second, widely used viral vector system is based on lentiviruses. The 
biggest advantage of lentiviral vectors is their ability to transduce minimally proliferating T 
cells (Naldini et al., 1996; Hu and Pathak, 2000). Moreover, they have a higher cargo 
potential, are not as susceptible to gene silencing and have a lower risk to insert in `hot 
spot´ regions which might further reduce the already low risk of malignant transformation 
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of the cell (Montini et al., 2006). However, safety and efficacy of lentiviral vectors are still 
under investigation. Recent advances are also made in the field of integrating non-viral 
vectors including DNA plasmid-based (Park et al., 2007; Till et al., 2008) and transposon-
based (Huang et al., 2008; Wilson et al., 2007) gene delivery methods. Further 
investigation of these systems will show their feasibility. Other approaches include 
messenger RNA (Mitchell et al., 2008; Zhao et al., 2010, Barret et al., 2011) or protein 
transfer. The transient nature of the transgene expression makes this a safe approach but 
its clinical value will have to be explored in future clinical trials.  
1.6.5 Phase I clinical studies employing first generation CARs 
Based on the antitumor effect of CAR engineered T cells in in vitro and in vivo models, 
first phase I clinical studies utilizing first generation CARs have recently been performed 
and completed. In one study, re-directed T cells were targeted against the ovarian cancer-
associated -folate receptor. Engineered T cells disappeared rapidly after adoptive T cell 
transfer with barely detectable levels one month after treatment and they showed no 
biological effect (Kershaw et al., 2006). Another study observed no clinical responses in 
patients with metastatic renal cell carcinoma treated with re-directed T cells recognizing 
carbonic anhydrase IX (CAIX). Furthermore, patients developed severe liver toxicities due 
to unexpected on-target effects against CAIX positive epithelial cells in the bile duct 
(Lamers et al., 2006; Lamers et al., 2007). The clinical studies mentioned above used 
retroviral vectors as gene delivery system, whereas Park et al. transferred electroporated 
CAR positive T cells directed against L1-adhesion molecule specifically expressed in 
neuroblastomas. In this study, one of six patients showed a partial response (Park et al., 
2007). Furthermore, Till et al. conducted a clinical study with electroporated T cells 
modified to recognize CD20, an antigen present on B cell lymphoma and mantle cell 
lymphoma. Although administration of low dose IL-2 prolonged persistence of modified T 
cells, the number of circulating CD20
+
 B cells did not decrease and antitumor effects were 
marginal (Till et al., 2008). A promising application of gene therapy was reported by Pule 
et al. after treating neuroblastoma patients with re-directed T cells recognizing 
diasialoganglioside GD2. Pule et al. engineered two different T cell populations: virus-
specific CTLs and bulk CTLs. Infusion of CAR engineered virus-specific T cells was safe 
and resulted in tumor regression or necrosis in half of the treated patients (Pule et al., 
2008).  
Although, results of most phase I trials with first generation CARs are clinically 
disappointing they proved safety and feasibility and are a first example of investigator-
initiated bench-to-bedside translational science. Major problems of first-generation CARs 
are their lack of expansion and persistence in vivo. This may result from eliciting an 
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immune response directed against the CAR and the subsequent elimination of re-directed 
T cells (Lamers et al., 2006) and/or sub-optimal culture conditions of T cells prior to 
infusion. Furthermore, it is becoming more apparent that a major factor contributing to 
poor persistence and function is the inability of the CAR to provide co-stimulatory events 
and fully activate the T cell without rendering it anergic.  
To compensate the lack of co-stimulation two approaches are currently explored. The first 
approach comprises the incorporation of various co-stimulatory domains in the CAR 
construct. Binding of these CARs to their specific antigen results in T cell activation, 
proliferation and IL-2 secretion without the need of cross-presentation by DCs (Maher et 
al., 2002; Vera et al., 2006). The second approach for providing co-stimulation targets 
antigen-specific CTLs which recognize through their native  TCR an antigen present on 
APCs. Thereby, T cells are getting re-stimulated in a physiological way and the CAR 
functions to re-direct those (Pule et al., 2008). 
1.6.6 Phase I clinical studies employing second and third generation CARs 
Currently, several clinical studies using second and third generation CARs are in 
progress. The group of Dr. Carl June demonstrated objective clinical responses in their 
recent trial (Porter et al., 2011) utilizing a second generation CAR construct against CD19 
in patients with chronic lymphoid leukemia. Re-infusion of these CAR
+
 T cells led to 
complete remission of chronic lymphoid leukemia in 2/3 patients and one partial remission 
(Kalos et al., 2011). Although, not many clinical responses have been reported up to now, 
two severe adverse events have occurred resulting in the patients´ death. One report by 
Morgan et al. stated the administration of a third-generation CAR directed against ERBB2. 
This resulted in immediate pulmonary toxicity and post mortem analyses revealed spiking 
serum cytokine levels. Most likely, low levels of ERBB2 expression on normal lung 
epithelial cells led to a cytokine storm and the rapid decline of the patient (Morgan et al., 
2010b). The second incident was reported after administration of a second-generation 
CAR re-directed against CD19 treating refractory chronic lymphoid leukemia patients. The 
patient became hypotensive and developed acute renal failure after adoptive T cell 
transfer. All signs were consistent with the clinical picture of acute sepsis and could not be 
traced back to the occurrence of tumor lysis syndrome. Therefore, the clinical trial protocol 
was modified and consequently fewer CAR positive T cells are infused into patients 
(Brentjens et al., 2010). 
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1.6.7 Strategies to limit unforeseen toxicity events 
As exemplified in these two unforeseen adverse events eminently attention needs to be 
directed towards toxicity effects of CAR re-directed T cells related to their distribution in 
normal tissue after adoptive transfer. Intravenous application of re-directed T cells shows 
antigen-independent pooling in the lungs and liver (Morgan et al., 2010b; Parente-Pereira 
et al., 2011). Furthermore, unwanted on-target effects describe the recognition of antigen 
expressed on non-malignant cells which result in antigen-specific activation of CAR re-
directed T cells outside the tumor tissue. This may result in (i) immediate cytotoxicity and 
/or (ii) late or sustained toxicity leading to the long term depletion of cells (Ertl et al., 2011). 
Immediate cytotoxicity may occur directly after infusion of re-directed T cells when 
massive activation can lead to the patient’s death. Special precautions need to be taken if 
CARs are directed against untested or endogenous antigens as high avidity receptors 
recognize their antigen and activate T cells at antigen levels which cannot be detected by 
conventional methods. Limiting such toxicity is achieved by employing dose-escalation 
schemes, splitting the T cell dose over several days (Brentjens et al., 2010) or using first 
generation CARs. The additional insertion of conditional suicide genes has limited 
potential for preventing acute toxicities as CAR T cells may act within minutes and 
symptoms only occur after severe damage has already happened (Morgan et al., 2010b). 
The other risk of long term depletion of cells necessary for normal function is exemplified 
for B cell malignancies which are treated with CAR T cells directed against CD19 or 
CD20. If CAR T cells would be persistent and functional a continuous depletion of B cells 
would be the result. If the chosen antigen is expressed in healthy tissue, like VEGF 
receptor 2 (VEGFR2) which is needed during angiogenesis, vasculogenesis, and wound 
healing etc. (Shibuya et al., 2006) the resulting medical conditions could be treated with 
drugs or alternatively, a suicide gene could be inserted in CAR T cells.  
1.6.8 Adoptive T cell therapy for multiple myeloma 
Multiple Myeloma (MM) is the second most common blood borne malignant disease and 
is characterized by neoplastic transformed plasma cells in the bone marrow (Palumbo and 
Anderson, 2011). Though extensive treatment regimens are available, MM is still 
considered an incurable disease. The immune system seems to be a critical factor for 
disease control in multiple myeloma since immune-modulatory drugs and allogeneic stem 
cell transplantation can achieve long lasting remissions in a subgroup of patients 
(Giaccone et al., 2011; Kyle and Rajkumar 2004). The curative effect of allogeneic stem 
cell transfer is, in part, an immunological effect mediated by T cells from the donor defined 
as graft versus myeloma effect (Bleakley and Riddell, 2004). Antigens expressed on 
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myeloma cells allowing graft versus myeloma effects are mainly minor histocompatibility 
antigens (Hambach and Goulmey, 2004). However, the recognition of minor 
histocompatibility antigens is associated with graft-versus host disease (GvHD), one of the 
most serious complications in allogeneic stem cell transfer. Therefore, the identification of 
new myeloma specific markers unrelated to histocompatibility antigens is of great interest. 
NY-ESO-1 is a promising target for immunotherapy, because NY-ESO-1 expression is 
found in malignant plasma cells with expression levels of 30 % at first diagnosis and up to 
60 % at relapse (van Rhee et al., 2005). At the National Institutes of Health (Bethesda, 
USA) are currently two phase I/II trials listed which recruit patients with advanced 
myeloma. In one trial, the investigators will infuse autologous genetically modified T cell to 
express a high affinity NY-ESO-1 TCR in HLA-A*02 positive patients and a high affinity 
Mage-A3 TCR in HLA-A*01 patients. Furthermore, one phase I clinical trial for multiple 
myeloma patients is conducted using autologous T cells engrafted with a CAR targeting 
the kappa light chain of immunoglobulins. These trial will also compare the functionality of 
first and second generation CAR grafted T cells.  
1.7 Aims of the thesis 
Adoptive T cell therapy with re-directed CAR
+
 T cells seems to be a highly promising 
approach to treat cancer. A widely expressed TAA is NY-ESO-1. Due to the intracellular 
location of the protein, it first needs to be degraded to peptide fragments, loaded onto HLA 
class I molecules and transported to the cell surface to be presented to CD8
+
 T cells. 
Multiple naturally occurring regulatory mechanisms of the immune system as well as the 
immunosuppressive tumor environment may lead to a deprivation of CD8
+
 T cells specific 
for NY-ESO-1 proteins. In prior studies, our group selected by phage display a Fab 
fragment which recognizes the NY-ESO-1157-165 peptide in the HLA-A*02:01 context. The 
corresponding scFv was used to construct a CAR to re-direct CD8
+
 T cells. The overall 
goal of the thesis project is to proof antigen-specific functionality of NY-ESO-1157-165/HLA-
A*02:01 specific re-directed T cells which ultimately should lead to the initiation of a phase 
I clinical trial for HLA-A*02:01 positive patients with NY-ESO-1 positive multiple myeloma. 
To demonstrate feasibility and functionality the following aims were specified: 
1. to generate first and second generation CAR constructs which recognize in a TCR 
manner the NY-ESO-1157-165/HLA-A*02:01 complex 
2. to investigate the functional potential of the generated re-directed T cells in vitro 
3. to phenotypically analyze subpopulations of the re-directed T cells 
4. to determine functional differences of the found subpopulations in vitro 
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5. to explore the in vivo functionality of re-directed T cells 
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2 Material and Methods 
2.1 Equipment 
Agarose Gel Documentation BioDoc-It Imaging System UVP, Upland, USA 
Autoclave V-100 Systec, Hühnenberg, 
Switzerland 
Cell counter CASY Cell Counter Model TT Roche Innovatis, Bielefeld, 
Germany 
Centrifuges:  
 Centrifuge 5804R Eppendorf, Hamburg, 
 Centrifuge 5810R  Germany 
 Centrifuge 5415D 
Flow Cytometers and Sorters:  
 FACScan  BD Biosciences, San Jose, 
 FACSCalibur USA 
 FACSCanto II  
 LSR II  
 FACSAria III  
Magnetic activated cell sorting MACS multistand & Miltenyi Biotec, Bergisch 
quadro MACS Gladbach, Germany  
NanoDrop 1000 Spectrometer ThermoScientific 
Wilmington, USA 
PCR cycler T300 Thermocycler Biometra, Göttingen, 
Germany 
Plate reader Wallac Victor2 1420 Multilabel Counter PerkinElmer, Waltham, USA 
Water purification Milli-Q Gradient System Millipore, Bedford, USA 
2.2 Plasmids and bacteria 
2.2.1 Plasmids 
 pCOLT-GalV (#392) 
Kind gift of Prof. Abken, Cologne, Germany;  
First described by Weijtens et al., 1998; 
Retroviral helper plasmid coding for GALV env protein 
 pHIT60 (#393) 
Kind gift of Prof. Abken, Cologne, Germany;  
First described by Weijtens et al., 1998; 
Retroviral helper plasmid coding for MLV gag and MLV pol protein 
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 BW431/26-CD28/CD3 (#607) 
Kind gift of Prof. Abken, Cologne, Germany;  
First described by Hombach et al., 2001; 
Plasmid coding for a CEA recognizing chimeric antigen receptor expressing CD28 and 
CD3 
Expression cassette codes for a fusion protein consisting of a L-leader sequence, a scFv 
recognizing carcinoembryonic antigen (CEA), a human CH2CH3 IgG domain and a 
CD28/CD3domain. 
 3M4E5-CD3 (#1044wt) 
Generated in our lab; 
Expression cassette codes for a fusion protein consisting of a L-leader sequence, the wt 
3M4E5 scFv recognizing the HLA-A*02:01/NY-ESO-1157-165 complex, a human CH2CH3 
IgG domain and aCD3domain. 
 3M4E5-CD28/CD3 (#1046wt) 
Generated in our lab; 
First described by Stewart-Jones et al., 2009 
Expression cassette codes for a fusion protein consisting of a L-leader sequence, the wt 
3M4E5 scFv recognizing the HLA-A*02:01/NY-ESO-1157-165 complex, a human CH2CH3 
IgG domain and a CD28/CD3domain. 
 T1-CD3 (#1044t1) 
Generated in our lab; 
Expression cassette codes for a fusion protein consisting of a L-leader sequence, the T1 
scFv recognizing the HLA-A*02:01/NY-ESO-1157-165 complex, a human CH2CH3 IgG 
domain and aCD3domain. 
 T1-CD28/CD3 (#1046t1) 
Generated in our lab; 
First described by Stewart-Jones et al., 2009 
Expression cassette codes for a fusion protein consisting of a L-leader sequence, the T1 
scFv recognizing the HLA-A*02:01/NY-ESO-1157-165 complex, a human CH2CH3 IgG 
domain and a CD28/CD3domain. 
2.2.2 Bacterial strain 
One shot TOP10 Chemically Competent E.coli Invitrogen, Karlsbad, USA 
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2.3 Media for bacterial growth 
 LB medium 
 10 g  Bacto Tryptone (BD, Sparks, USA) 
 5 g  Yeast extract (Sigma-Aldrich, St.Louis, USA) 
 5 g  NaCl 
 1 l  dH2O 
 Medium was heat sterilized 
 LB-Amp 
 LB medium with 100 g/ml ampicillin (Sigma-Aldrich, St. Louis, USA)  
 added after heat sterilization 
 LB-Amp plates 
 LB-Amp with 1.5 % (w/v) Difco Agar (BD, Sparks, USA)  
 added before sterilization 
2.4 Enzymes 
Phusion High-Fidelity DNA Polymerase Finnzymes, Espoo, Finland 
Restriction enzyme NcoI New England BioLabs, Ipswich, USA 
Restriction enzyme BamH1 New England BioLabs, Ipswich, USA 
Streptavidin-Horse Radish Peroxidase BD Biosciences, San Diego, USA 
2.5 Primer 
Primer designation Primer sequence (5’-3’) 
f1-Part2Lkappa-3M CTA ATC AGT GCC TCA GTC ATA ATG TCT AGA ATG GCG GAG 
GTG CAG CTG 
f2-NcoI-Part1Lka CGT ACC ATG GAT TTT CAG TGT CAG ATT TTC AGC TTC ATG 
CTA ATC AGT GCC TCA GTC ATA ATG TC 
r-BamH1-3M4E5 GAT AGG ATC CAC TGT GGG GTT GG 
f-VH-peptide linker ATG GAT GTG TGG GGC CAG G 
f-CD3 AGG ACA CCT ACG ACG CCC TT 
Table 2-1: Primer designations and primer sequences 
  
24 Material and Methods 
2.6 Buffers, DNA dyes and ladders 
Chemical reagents listed here were purchased from the following manufacturers: Merck 
(Darmstadt, Germany), Sigma-Aldrich (St. Louis, USA), Kantonsapotheke (Zürich, 
Switzerland), Roth (Karlsruhe, Germany); Fluka (Buchs, Switzerland). DNA ladders were 
purchased from New England BioLabs (Ipswich, USA). 
2.6.1 Buffers 
 TAE 
 2 mM TRIS Ultra 
 0.25 mM Acetic acid 
 0.5 mM  EDTA 
 PBS 
 150 mM NaCl 
 10 mM  Na2HPO4 
 1.5 mM  KH2PO4 
 0.05 % PBST 
 99.95 % (v/v) PBS 
 0.05 % (v/v) Tween20 
 Flow cytometry buffer 
 2 % (v/v) FBS, heat inactivated 
 0.01 % (w/v) Sodium azide 
 5 mM EDTA 
 1 l PBS 
 Blocking solution 
 10 % (v/v) FBS, heat inactivated 
 90 % (v/v) PBS 
 Triton X buffer 
 150 mM  NaCl 
 50 mM Tris-HCl 
 10 mM MgCl2 
 1 % (w/v) TritonX 
2.6.2 DNA dyes and ladders 
 5x DNA loading dye 
 50 % (v/v) TAE 
 50 % (v/v) Glycerol 
 0.4 % (w/v) Orange G 
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 DNA ladder 
 20 % (v/v) 100 bp or 1 kb DNA ladder (New England BioLabs, Ipswich,  
  USA) 
 40 % (v/v) 5x DNA loading dye 
 40 % (v/v)  dH20 
2.7 Antibodies, Fab molecules, tetramers, conjugates, and 
cytokines 
2.7.1 Antibodies 
Anti-human HLA-A,B,C-FITC Biolegend, San Diego, USA 
Mouse IgG2a,  – FITC Isotype control Biolegend, San Diego, USA 
Anti-human CD8-FITC eBioscience, San Diego, 
USA 
Anti-human CD3-PE-Cy7  BD Biosciences, San Jose, 
USA 
Anti-human IgG-PE Southern Biotech, 
Birmingham, USA 
Anti-human CCR7-FITC eBioscience, San Diego, 
USA 
Anti-human CD45RA-PerCp-Cy5.5 eBioscience, San Diego, 
USA 
Anti-human CD57-Biotin BD Biosciences, San Jose, 
USA 
Anti-human CD28-APC BD Biosciences, San Jose, 
USA 
Anti-human CD27 APC-H7 BD Biosciences, San Jose, 
USA 
Anti-human IFN-PE-Cy7 BD Biosciences, San Jose, 
USA 
Anti-human IL-2-PerCp-eFlour710 eBioscience, San Diego, 
USA 
Anti-human CD8 microbeads Miltenyi Biotec, Bergisch 
Gladbach, Germany 
Anti-human IgE antibody Biolegend, San Diego, USA 
Biotin-AffiniPure F(ab’)2 fragment goat anti-human IgG (H+L) Jackson Immuno Research, 
Suffolk, UK 
Human OKT3 eBioscience, San Diego, 
USA 
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Human CD28 (co-stimulatory) eBioscience, San Diego, 
USA  
2.7.2 Tetramer 
PE conjugated HLA-A*02:01/NY-ESO-1157-165 tetramer LICR, Lausanne, 
Switzerland 
2.7.3 Conjugate 
Streptavidin-PE-Cy7 eBioscience, San Diego, 
USA 
2.7.4 Fab molecules 
AI anti-idiotype Fab A4 in house, Zurich, Switzerland 
Control Fab (B1) in house, Zurich, Switzerland 
2.7.5 Cytokines 
Recombinant human IL-2 ImmunoTools, Friesoythe, 
Germany 
Recombinant human IL-15 ImmunoTools, Friesoythe, 
Germany 
2.8 Kits 
BD Cytofix/Cytoperm Kit BD Biosciences, San 
Diego,USA 
BD OptEIA Set Human IFN BD Biosciences, San 
Diego,USA 
BD OptEIA Set Human IL-2 BD Biosciences, San 
Diego,USA 
QIAGEN Plasmid Maxi Kit QIAGEN, Hilden, Germany 
QIAprep Spin Miniprep Kit QIAGEN, Hilden, Germany 
QIAquick Gel Extraction  QIAGEN, Hilden, Germany 
Rapid DNA Ligation Kit Roche Diagnostics, 
Mannheim, Germany 
REDTaq Ready Mix Sigma-Aldrich, St. Louis, 
USA 
DELFIA Eu labelling Kit Perkin Elmer, Waltham, USA 
MycoAlert Mycoplasma Detection Kit  Lonza Cologne GmbH, 
Cologne, Germany 
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2.9 Cell culture media, reagents and additives 
RPMI 1640 media with Glutamax Gibco, Carlsbad, USA 
Hygromycin B Gibco, Carlsbad, USA 
Penicillin/Streptomycin Gibco, Carlsbad, USA 
Fetal Bovine Serum (FBS) Gibco, Carlsbad, USA 
Heat inactivation: 56 °C for 30 min 
0.05 % Trypsin-EDTA Gibco, Carlsbad, USA 
Dimethylsulfoxide (DMSO) Merck, Darmstadt, Germany 
2.10 Cell lines and primary cells 
 293T 
Kind gift of Prof. Abken, Cologne, Germany 
Derived from 293 cells, carries the SV40 large T antigen 
 U266 
Kind gift of Prof. Keilholz, Charité, Berlin 
Human multiple myeloma cell line, secrets hIgE molecules 
 T2-1B 
Held et al., 2004 
Minigene-transfected T2 cell line expressing NY-ESO-1157-165/HLA-A*02:01-complexes 
 T2-1A 
Held et al., 2004 
Minigene-transfected T2 cell line expressing NY-ESO-1157-167/HLA-A*02:01-complexes 
2.11 Mice 
Five to eight weeks old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice, commonly known as 
NOD scid gamma (NSG), were purchased from Jackson Laboratories (Bar Harbor, ME, 
USA) and maintained under specific pathogen-free conditions on Institutional Animal Care 
and Use Committees (IACUC) protocols. 
2.12 Software 
Cell Quest Pro 4.0.2 BD Biosciences, San Jose, USA 
FACSDiva BD Biosciences, San Jose, USA 
FlowJo 7.5  Treestar, Ashland, USA 
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GraphPad Prism V 5.01 for Windows Graph Pad Software, San Diego, USA 
Microsoft Office Excel 2003 Microsoft, Redmond, USA 
2.13 Bacterial culture methods 
2.13.1 Growth of bacteria in suspension 
For bacterial expansion, LB-Amp media was inoculated with 15 l of bacteria from a 
respective glycerol stock and incubated over night at 37 °C and 250 rpm. 
2.13.2 Growth of bacteria on agar plates 
Freshly transformed Top10 bacteria in SOC media were plated on LB-Amp agar plates over 
night at 37 °C. 
2.13.3 Glycerol stocks of bacteria 
Bacterial suspension was diluted with glycerol (50 % (v/v), Sigma-Aldrich, St.Louis, USA) 
and after thorough mixing stored at -80 °C. 
2.13.4 Transformation of competent E.coli cells 
After ligation of DNA fragments, the mixture was added to one vial of TOP10 competent 
E.coli cells and incubated for 30 min on ice. Cells were heat-shocked for 45 s at 42 °C and 
directly afterwards placed on ice for 1 min. 250 l SOC media were added followed by a 1 
hour incubation period at 37 °C and 250 rpm.  
2.14 Molecular biology techniques 
2.14.1 Purification of DNA  
For purification of DNA several kits were used according to the manufacturer’s protocol. 
DNA fragments which have been separated by gel electrophoresis were recovered using 
QIAquick Gel Extraction kit. Small and large amounts of plasmid DNA were purified from 
E.coli bacteria using the QIAprep Spin Miniprep kit or the QIAGEN Plasmid Maxi kit, 
respectively.  
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2.14.2 Determination of DNA concentration 
Using the NanoDrop DNA concentration was determined by measuring the absorbance at 
260 nm and at 280 nm to account for impurities. DNA with an A260 nm/A280 nm of 1.8-2 
was considered as pure. 
2.14.3 Agarose gel electrophoresis 
1 % (w/v) agarose gels prepared with TAE buffer and 10 g/ml ethidium bromide (EtBr) were 
used for analytical or preparative separation of DNA fragments. The DNA was mixed with a 
5x DNA loading dye. 100 bp and 1 kb DNA ladders were applied to individual gel pockets as 
size standards. A voltage of 100-120 V was applied to the gels. Separation of DNA 
fragments was monitored under UV light. 
2.14.4 DNA amplification by polymerase chain reaction (PCR)  
The principle of PCR is thermal cycling, comprising of repeated cycles of DNA melting and 
the subsequent enzymatic amplification of DNA pieces. Thereby are several magnitudes of 
copies of a particular DNA sequence generated.  
The reaction was carried out in a temperature controlled T300 thermocycler. 
Reaction conditions for DNA amplification were as follows: 
 Template DNA 10-100 ng 
 Forward Primer 20 pmol 
 Reverse Primer 20 pmol 
 dNTPs 200 M 
 Phusion polymerase 1 U 
 5x GC buffer 10 l 
 dH20 volume was adjusted to 50 l 
 
 
Following cycling conditions were applied: 
 Initial denaturation 96 °C 6 min   
 Denaturation 95 °C 45 s 
 Annealing 55 °C 45 s 
 Elongation 72 °C 1 min, back to step 2, 30 cycles 
 Final elongation 72 °C 10 min 
2.14.5 Digestion of DNA with restriction endonucleases 
Digestion of vector and PCR products was conducted in two steps as follows: 
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Step 1: Template 1 g 
 NcoI 1 U 
 NEB buffer #4 5 l 
 dH2O volume was adjusted to 50 l 
 Incubation at 37 °C for 30 min 
Step 2: 1 U BamHI was added to the reaction  
 Incubation at 37 °C for 30 min 
2.14.6 Ligation of DNA 
DNA fragments were ligated using the Rapid DNA Ligation kit according to the 
manufacturer’s protocol. The insert: vector ratio was 3:1.  
2.14.7 Colony PCR 
To verify correct insertion of the DNA fragment of interest into the plasmid a colony PCR 
reaction was carried out with the REDTaq ReadyMix according to the manufacturer’s 
protocol and using the primer pairs f2-NcoI-Part1Lka and r-BamHI-2M4E5. Cycling 
conditions for amplification of DNA were applied. The reaction was analyzed via agarose gel 
electrophoresis.  
2.14.8 Sequencing 
Successful cloning of all plasmids was confirmed by sequencing the flanking regions of the 
insertion site (primers: f2-NcoI-Part1Lka, f-VH-peptide linker, and f-CD3). Sequencing was 
performed by Microsynth AG (Balgach, Switzerland). 
2.14.9 Cloning strategy of high affinity chimeric antigen receptors 
To construct retroviral expression vectors plasmids were used derived from the retroviral 
expression vector pBullet. pBullet codes for a SV40 ori, an ampicillin resistance and a CMV 
promoter controlling the expression cassette. It is derived from pStitch by deleting two NcoI 
and one XhoI restriction sites (Weijtens et al., 1998). 
In preliminary studies our group isolated two Fab molecules recognizing the NY-ESO-1157-165 
peptide in the context of HLA-A*02:01 molecules. They differ in their affinity to bind their 
specific antigen: the wild type (3M4E5) variant possesses a KD value around 60 nM and the 
type1 (T1) variant around 2 nM. Based on the sequences of these Fab molecules single 
chain Fv (scFv) fragments were generated (Stewart-Jones et al., 2009).  
3M4E5-CD28/CD3 and 3M4E5-CD3each cloned into one individual pBullet vector were 
used as starting vectors (Stewart-Jones et al., 2009). Their expression cassette codes for a 
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fusion protein consisting of a L-leader sequence, a scFv recognizing the HLA-A*02:01/NY-
ESO-1157-165 complex, a CH2CH3 IgG domain and a CD28/CD3domain or aCD3domain, 
onlyTo exchange the 3M4E5 scFv with the T1 scFv, the L leader sequence and the 
appropriate restriction sites were added to the T1 scFv in two PCR steps using in a first step 
the primer pair f1-part2Lkappa-3M and r-BamHI-3M4E5 and in a second step pair f2-NcoI-
Part1Lka and r-BamHI-3M4E5. PCR products were purified via gel electrophoresis and 
subsequent gel extraction. 3M4E5-CD28/CD3 and 3M4E5-CD3vectors and the end PCR 
product of L-T1 scFv were digested with NcoI and BamHI and ligated. Successful insertion 
of the L-T1 scFv was analyzed by colony PCR and verified by sequencing.  
2.15 Cell culture techniques and immunobiological methods 
2.15.1 Cultivation of cell lines 
Stable-transfected HLA-A*02:01-positive T2 cell lines 1A and 1B expressing HLA-A*02:01 
restricted NY-ESO-1 peptides 157-167 (T2-1A) and 157-165 (T2-1B), respectively were 
cultivated in R10 media [RPMI1640 GlutaMax supplemented with 10 % fetal bovine serum 
(FBS) (v/v), 50 U/ml penicillin and 50 g/ml streptomycin] supplemented with 2.5 g/ml 
hygromycin B. 293T and U266 cells were cultivated in standard R10 media only. All cells 
were cultured at 37 °C and 5 % CO2. Adherent cell lines were detached from cell culture 
flasks using trypsin-EDTA. Cells were frozen down using freezing media [90 % (v/v) FBS, 10 
% (v/v) DMSO]. 
2.15.2 Mycoplasma test 
Every three months, each cell line was tested for mycoplasma using MycoAlert Mycoplasma 
Detection Kit (Lonza Cologne GmbH, Cologne, Germany) according to the manufacturer’s 
protocol.  
2.15.3 Determination of cell number and viability 
Cell number, size distribution and viability of cell lines and primary human cells were 
determined by CASY Cell Counter + Analyzer System Model TT. The method is based on 
electrical current exclusion which measures the volume and viability of the cell in a dye-free 
setting.  
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2.15.4 Retroviral transduction of peripheral blood CD8
+ T cells 
Peripheral blood mononuclear cells were obtained from healthy donors by Ficoll PaqueTM 
Plus (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) density gradient centrifugation. 
CD8 T cell subsets were isolated using MACS microbeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to the manufacturer’s protocol. Positive selection with anti-
human CD8 microbeads typically resulted in a ≥ 95% pure CD8
+
 population. Purified CD8
+
 T 
cells were cultivated for 48 h in R10 media in the presence of 400 IU/ml human recombinant 
IL-2, anti-human OKT3 mAb and anti-human CD28 mAb (each at 100 ng/ml). 
For production of infectious gibbon-ape leukemia virus pseudotyped retroviruses, 293T cells 
were seeded at 2.5*105 cells/ well (6-well plate) and co-transfected with the retroviral helper 
plasmids pHIT60 and pCOLT (each 0.75 μg DNA) together with the retroviral expression 
vector DNA (1.5 μg DNA) using 12 μl Fugene transfection reagent per well (Roche 
Diagnostics GmBH, Mannheim, Germany, according to the manufacturer’s protocol). If CAR 
transduced CD8
+
 T cells were used for in vivo studies, 7.5*105 293T cells/ well were plated 
and irradiated with a single dose of 3000 Rad after 24 h of co-transfection. 
Activated CD8
+
 T cells were infected for 96 hours in the presence of 100 IU/ml IL-2 by co-
cultivation with 293T cells which are transiently producing high titers of infectious retrovirus. 
CD8
+
 T cells were harvested and monitored for expression of CAR using flow cytometry. 
2.15.5 Immunoflourescence staining and analyses 
Cells were washed in flow cytometry buffer and surface stained with directly labeled or 
biotinylated antibodies (20 min at 4°C), or with peptide-MHC class I tetramer complexes (30 
min at RT). Thereafter, cells were fixed using 500 μl of FACSLyse buffer (BD Biosciences, 
San Diego, USA) (10 min at RT). Cells were then washed, resuspended in flow cytometry 
buffer and stained with tandem conjugates (20 min at RT). After washing, cells were 
resuspended in flow cytometry buffer and analyzed by flow cytometry. 
For intracellular cytokine staining, cells were stimulated with 2 μg/ml AI anti-idiotype Fab A4 
or control Fab for 12 h in the presence of Golgi Plug (BD Biosciences, San Diego, USA). Cell 
surface staining was performed as described above, followed by fixation and 
permeabilization using 250 μl of Cytofix/Cytoperm solution (20 min at 4 °C). After washing 
with 1x Perm/Wash buffer (BD Biosciences, San Diego, USA), cells were stained with 
directly labeled antibodies against IL-2 and IFN (30 min at 4 °C). After another round of 
washing, flow cytometry analyses was performed using a LSR II, FACSCanto II, 
FACSCalibur or FACScan flow cytometer. All data were analyzed using FlowJo software. At 
least 150,000 cells were collected for 6- and 4-colour flow cytometry analyses.  
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2.15.6 Cell Sort 
To isolate CCR7
+
 and CCR7
–
 CAR-grafted T cell subsets, CD8
+
 T cells were stained with 
hIgG and CCR7 antibody and sorted to > 90 % purity using FACSAria III. Cells were either 
used for in vivo experiments or plated in a pre-coated 96-well flat bottom plate (2 μg/ml of AI 
anti-idiotype Fab and control Fab overnight, 4 °C) at a density ranging from 1.6*104/well to 
3.7*105/well depending on the sort efficiency and incubated in standard media supplemented 
with 50 ng/ml IL-15 for a total of 10 days at 37 °C. After 24 h incubation, supernatants were 
taken for cytokine monitoring and cells were stained for hIgG and CCR7 expression and 
analyzed via flow cytometry after 10 days of incubation. 
2.15.7 Cytokine and hIgE secretion assays 
Cytokine production was assessed by performing sandwich ELISA assays. Therefore, 
supernatants of co-cultivated effector and target cells were collected after 24 hours of 
incubation. IFN and IL-2 levels were detected using BD OptEIA set human IFN and BD 
OptEIA set human IL-2 kits, respectively, according to the manufacturer’s instruction. 
To assess tumor burden, mouse blood was taken from the tail vein, centrifuged for 20 min at 
1500 rpm, RT and the sera was collected. Subsequently, sera levels of hIgE proteins were 
measured. For that purpose, 96-well maxisorp microtiter plates (NUNC, Rochester, USA) 
were coated with 1 ug/ml purified anti-human IgE antibody diluted in carbonate buffer (1 h at 
37 °C). Plates were washed three times in 0.05% Tween20/PBS and then blocked with 10 % 
FBS/PBS (1h at RT). After three washing steps, samples and standard (human IgE protein, 
Abcam, Cambridge, USA) were added to the plate and incubated (2 h at RT). The plates 
were washed five times and then incubated (1 h at RT) with 1 ug/ml Biotin- AffiniPure F(ab’)2 
fragment goat anti-human IgG (H+L) diluted in 10 % FBS/PBS. After five washing steps, 1 
ug/ml Streptavidin-Horse Radish Peroxidase was added (1 h at RT). Plates were washed five 
times and ELISAs developed with SureBlue (KPL, Gaithersburg, MD), stopped using H3PO4 
(Sigma-Aldrich, St. Louis, USA) and measured at 450 nm. The detection limit for human IgE 
was 0.125 ng/ml.  
2.15.8 Europium release assay 
Specific cytotoxicity of CAR grafted T cells was analyzed by a europium release assay 
according to the manufacturer’s protocol (Perkin Elmer, Waltham, USA) with minor 
modifications. Briefly, target cells (1A, 1B and U266) were labeled with 2,2’:6’,2”-terpyridine-
6,6”- dicarboxylic acid acetoxymethylester (BATDA) (2 h at 37 °C). After 5 washing steps, 
target cells were seeded at a density of 104 cells per 96-well and co-cultured with effector 
cells at different effector: target (E/T) ratios (2 h at 37 °C). Supernatant was harvested and 
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incubated with DELFIA Europium solution (15 min at RT) under constant vibration. The 
ligand released from dead cells forms together with europium a highly stable fluorescent 
chelate (EuTDA) which was measured in a time-resolved Victor2 fluorometer. Maximal 
EuTDA formation was determined as the mean of three wells of target cells lysed with 
TritonX buffer. Background and spontaneous release were determined from triplicate wells 
containing R10 media only or target cells alone, respectively.  
The specific cytolysis of target cells (%) was calculated by the equation:  
                                 ( )       
(                     (      )                       (      ))
 (                (      )                       (      )) 
 
2.16 Xenograft model 
To investigate the in vivo potential of re-directed T cells, an immuno-compromised mouse 
model was employed, so called NSG mice (strain name: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ). 
This mutant mouse strain combines the NOD.SCID background with an IL-2 receptor gamma 
chain deficiency. As a consequence, these mice lack mature B cells, T cells, and functional 
NK cells. Furthermore, they are deficient in cytokine signaling which leads to a better 
engraftment of hematopoietic stem cells and peripheral blood mononuclear cells (PBMCs). 
Following irradiation of mice, intravenous injection of the human multiple myeloma cell line 
U266 resembles the pathogenesis of the disease (Miyakawa et al., 2004). Additionally, U266 
cells are HLA-A*02:01
+
 and express endogenously NY-ESO-1 making them an excellent 
target for NY-ESO-1157-165/HLA-A*02:01 CAR expressing T cells. 
2.16.1 In vivo tumor growth 
Mice were irradiated on a single fraction of 2.4 Gy followed by subsequent injection of either 
2*107 U266 cells intravenously (i.v.), 107 U266 cells i.v., 6*106 U266 cells i.v. or 2*107 U266 
cells intraperitoneally (i.p.). In vitro, 106 U266 cells secrete about 300 ng/ml of human hIgE in 
24 hours. To monitor growth of malignant plasma cells, blood samples were taken after 
inoculation. Sera were collected and hIgE production was analyzed by ELISA (material and 
methods section 3.15.6) as indicated by figure 2-1.  
Material and Methods 35 
 
Figure 2-1: Establishment of in vivo growth of U266 cells.  
As indicated, four different doses/ injection routes of U266 cells were established into sublethal irradiated NSG 
mice. The yellow arrows indicate the days of blood draw after U266 injection. Sera were isolated from blood and 
were used to measure hIgE levels as surrogate marker for tumor growth via ELISA.  
2.16.2 Analyses of U266 growth in the bone marrow, spleen, and blood 
To confirm U266 growth in the bone marrow of mice, tibia was resected and subsequently 
decalcified and H&E stained (Pathology Department, Providence Portland Medical Center, 
Portland, OR, USA).  
Furthermore, bone marrow of tibia and femur, spine as well as blood samples and 
splenocytes were obtained to analyze U266 tumor growth. Spleen tissue was pierced and 
splenocytes were teased out both using curved watchmaker forceps. Splenocytes and 
spleen tissue were filtered through a 70 µm sieve. Afterwards, a centrifugation step was 
carried out to spin down the cells at 1500 rpm for 5 min, RT. The supernatant was discarded 
and the cells were resuspended in 1 ml ACK buffer for 3 min at RT to lyse erythrocytes. Tibia 
and femur from mice were excised using scissors and by breaking apart at joints the intact 
bone was freed from flesh. The bones were cut on both ends to open up the bone. R10 
media was aspirated into a syringe, a 27G needle was attached on top. The needle was 
inserted into the opened bones and the marrow was flushed out (also for spine). The solution 
was pipetted up and down to break aggregates. The cell solution was filtered through a 70 
µm sieve, pelleted and resuspended in 1 ml ACK buffer for 3 min at RT. Blood samples were 
collected from the tail vein and erythrocytes were lysed using ACK. All samples were stained 
with monoclonal antibodies as described in material and methods section 3.15.4. 
2.16.3 Treatment protocols of U266 tumors 
Five days after 107 U266 tumor cell i.v. injection, different doses of re-directed CD8
+
 T cells 
were administered i.v. followed by six bi-daily injections of 90 000 IU IL-2. The treatment 
protocol is displayed in figure 2-2. The number of BW431/26-CD28/CD3 re-directed T cells 
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administered to the control groups was adjusted according to the transduction efficiency. 50 
% of T cells expressed CARs, irrespective of the individual constructs.  
 
Figure 2-2: Treatment protocols of U266 tumors. 
Treatment started after 5 days of i.v. injection of 10
7
 U266 cells into sublethal irradiated NSG mice. In a first 
setting, mice were i.v. injected with 10
6
 T1-CD28/CD3 T cells (transduction efficiency 50 %) and with the same 
amount of BW431/26-CD28/CD3/ bulk T cells as specificity control. Group 3 served as tumor growth control. In a 
second setting, tumor bearing mice were treated with 10
7
 T1-CD28/CD3 T cells and their number equivalent of 
BW431/26-CD28/CD3/ bulk T cells. As before, group 3 did not receive any treatment. 
2.17 Statistical analyses 
Data were analyzed with Graph Pad Prism version 5.00 for Windows (GraphPad Software, 
San Diego, CA). Student’s unpaired or paired t-tests were performed between two groups of 
interest. Furthermore, Mann-Whitney U-test was employed to determine significances 
between different groups of mice.  
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3 Results 
3.1 Generation of re-directed CD8+ effector T cells expressing 
CARs with specificity for HLA-A*02:01/NY-ESO-1157-165 peptide 
complex 
In previous studies, our group isolated a Fab molecule (3M4E5) recognizing the NY-ESO-
1157-165 peptide in the context of a HLA-A*02:01 molecule. This Fab fragment was affinity 
matured to achieve higher peptide binding. Two light chain mutations improved the affinity of 
the newly generated T1 Fab to 2-4 nM compared to the 3M4E5 Fab which possesses a KD 
value around 60 nM (Stewart-Jones et al., 2009). A scFv molecule was constructed based on 
the sequence of the T1-Fab molecule. This scFv was used as antigen binding domain for a 
CAR construct. Prof. Abken kindly provided his optimized vector system pBULLET already 
including either the CH2/3 IgG-CD28-CD3 or the CH2/3 IgG-CD3 domain only. The T1 
scFv was extended with an L leader sequence and cloned by appropriate restriction digest 
and subsequent ligation in the two expression cassettes, thereby generating fully functional 
chimeric antigen receptors (figure 3-1).  
 
Figure 3-1: Gel documentation of single PCR and restriction digest steps.  
Panel A shows the prolongation of the T1 scFv via 2 PCR steps. PCR product 1 (PCR1) revealed a size of 803 
bp. This was used as template for PCR2 which resulted in a size of 837 bp, comprising the complete sequence of 
the L leader together with the T1 scFv. Figure B depicts the restriction digest of the parental pBullet vectors 
(3M4E5-CD3 and 3M4E5-CD28/CD3and of scFv T1 PCR2. 
To re-direct T cells, human PBMCs were isolated from buffy coats and positively selected for 
CD8 expression. Retroviruses were generated employing transient co-transfection of 293 T 
cells with the respective CAR expression cassette and two helper plasmids, one encoding 
gag and pol, the other env. Co-cultivation of 293T cells with activated human CD8
+
 T cells 
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led to retroviral transduction resulting in the generation of re-directed T cells expressing 
CARs. These CARs consisted of a scFv molecule recognizing the HLA-A*02:01/ NY-ESO-
1157-165 peptide complex linked to a human CH2/3 immunoglobulin domain and a CD3 
signaling domain with (T1-CD28/CD3) and without (T1-CD3) a CD28 co-stimulatory 
domain. Re-directed T cells expressing a CAR recognizing carcinoembryonic antigen (CEA) 
with a CD28 co-stimulatory domain and a CD3 signaling domain (BW431/26-CD28/CD3, 
kind gift of Prof. Abken) were used as control (Hombach et al., 2001). The schematic 
representation of the re-directed T cells is shown in figure 3-2. 
 
 
 
 
Figure 3-2: Schematic presentation 
of re-directed T cells including the 
different CARs. 
A: Re-directed T cells recognizing NY-
ESO-1157-165 peptide in the context of 
HLA-A*02:01 without CD28 co-
stimulatory (T1-CD3) domain; B: Re-
directed T cells recognizing NY-ESO-
1157-165 peptide in the context of HLA-
A*02:01 with CD28 co-stimulatory 
domain (T1-CD28 /CD3); C: Re-
directed T cells recognizing CEA with 
CD28 co-stimulatory domain 
(BW431/26-CD28/CD3). 
 
Cell surface expression of CARs on retrovirally transduced CD8
+
 T cells was assessed by 
detecting the human CH2/3 immunoglobulin domain (hIgG) using flow cytometry (Figure 3-2 
A, B, C and D). After transduction, approximately 45% (median 44.42 % for all constructs, 
range: 11.06% -79.05%) of CD8
+
 T cells expressed the respective receptor. Antigen 
recognition of the immune-receptor on the cell surface was measured by HLA-A*02:01/NY-
ESO-1157-165 peptide tetramer binding (figure 3-3 E, F, G and H). The percentage of T cells 
expressing the CAR mirrored tetramer staining with no significant difference between 
constructs T1-CD28/CD3 and T1-CD3. As expected, the tetramer did not bind to the 
control CAR BW431/26-CD28/CD3 which recognizes CEA. 
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Figure 3-3: Transduction efficacy of CD8
+
 T 
cells.  
Assessment of transduction efficiency by staining 
of the CH2/3 immunoglobulin linker domain with 
anti-hIgG mAb (A-D). Antigen binding of the CAR 
constructs was characterized by staining with a 
HLA-A*02:01 restricted NY-ESO-1157-165 
(SLLMWITQC) peptide-specific, PE conjugated 
tetramer (E-H). 
3.2 Re-directed CD8+ T cells lysed target cells and secreted IFN 
in an antigen-specific manner 
To demonstrate functionality of re-directed T cells in vitro, europium release assays were 
performed to indicate specific lysis of target cells. Stable-transfected HLA-A*02:01-positive 
T2 cells expressing HLA-A*02:01 restricted NY-ESO-1 peptides 157-165 (T2-1B, figure 3-4 
A) and 157-167 (T2-1A, figure 3-4 B) served as target cell lines. NY-ESO-1 peptides of 
different length were used to test for antigen specificity. There was significantly higher 
specific lysis of target cells when re-directed T cells were transduced with T1-CD28/CD3 
CAR compared to T1-CD3 (figure 3-4 C). Furthermore, the myeloma cell line U266 was 
used to assess the ability of re-directed T cells to lyse cells endogenously expressing NY-
ESO-1 in the context of HLA-A*02:01. Cell lysis was target antigen specific since only T1-
CD28/CD3 and not BW431/26-CD28/CD3 recognized U266 cells (figure 3-4 E). 
IFN secretion was assessed by ELISA to demonstrate specific cytokine release. Re-directed 
T cells expressing the T1-CAR with the CD28 signaling domain secreted significantly higher 
antigen-specific IFN Moreover, T1-CD3 CAR expressing re-directed T cells did not secrete 
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IFN in an antigen specific manner (figure 3-4 D). Control re-directed T cells recognizing CEA 
revealed only background levels of cell lysis and IFN release. 
 
Figure 3-4: Representative experiment showing antigen-specific cytolysis of CAR re-directed CD8
+
  
T cells.  
To demonstrate antigen specific cell lysis, re-directed T cells recognizing CEA (BW431/26-CD28/CD3) and NY-
ESO-1157-165 peptide with (T1-CD28/CD3) and without CD28 co-stimulatory domain (T1-CD3) were co-cultured 
with stable-transfected T2 cells expressing HLA-A*02:01 restricted NY-ESO-1 peptides 157-165 (A) and 157-167 
(B) at different effector to target ratios. Panel C depicts lysis of target cells at an effector: target ratio of 4:1 over 
10 pooled experiments. To further show antigen specific cytokine secretion supernatants of co-cultivated cells 
were analyzed for IFNPanel D depicts IFNrelease after 24 h of co-cultivation at an effector: target ratio of 4:1 
over 10 pooled experiments. Re-directed T cells recognizing CEA (BW431/26-CD28/CD3) and NY-ESO-1157-165 
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peptide (T1-CD28/CD3) were cultured with the HLA-A*02:01 positive and endogenously NY-ESO-1 expressing 
myeloma cell line U266 at different effector to target ratios (E). ***p<0.001, *p<0.05 
3.3 CAR transduced T cells included subpopulations with 
effector and memory phenotype 
Since expression of the two CARs resulted in immediate antigen specific functionality, CAR 
transduced T cells were phenotypically analyzed and expected to consist of subpopulations 
with effector T cells (TEFF). Therefore, 6-color flow cytometry analysis (anti-hIgG, anti-CCR7, 
anti-CD57, anti-CD45RA, anti-CD28, anti-CD27) was employed to delineate sup-populations 
of re-directed T cells (hIgG positive cells) as depicted in figure 3-5.  
 
Figure 3-5: Representative phenotypical characterization of CD8
+
 T cells expressing the T1-CD28/CD3 
CAR by multi-parametric flow cytometry.  
Pre-gated hIgG
+
CCR7
+
 or hIgG
+
CCR7
–
 T cells were arrayed in a CD45RA vs. CD57 2-parameter dot-plot. Cells 
in each of the four quadrants were then further subdivided by gating through CD27/CD28 dot-plots. 
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T cells from eleven consecutive donors were analyzed three days after transduction. Re-
directed T cells included a CCR7
–
 population which could be separated into subpopulations 
with TEFF phenotype (CCR7
–
CD45RA
+
CD57
+
CD27
+/–CD28
–
) and TEM phenotype (CCR7
–
CD45RA
–
CD57
–
CD27
+
CD28
+/–) (Petrausch et al., 2006). Furthermore, the CCR7
+
 population 
included cells with a TCM phenotype (CCR7
+
CD45RA
–
CD57
–
CD27
+
CD28
+
) (figure 3-6 A). 
Comparison of all 11 donors showed no significant overall difference between both CARs 
(with and without CD28 signaling domain). However, transduction of the different CAR 
constructs resulted in a statistically significant different composition of single sub-phenotypes 
which included TEMRA, late and early TEM and TEFF. Interestingly, phenotypical comparison of 
re-directed and non-transduced T cells revealed the same T cell distribution pattern (figure 3-
6 B).  
 
Figure 3-6 : Subpopulation signatures of transduced hIgG
+
CD8
+
 T cells (A) and non-transduced hIgG
–
CD8
+
 T cells (B) pooled over 11 individual donors 3 days after retroviral transduction. 
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The resulting 32 subpopulations of hIgG
+
CD8
+
 T cells were displayed on the X axis and were divided into 16 
CCR7
+
 and 16 CCR7
–
 subpopulations. Subpopulations signatures were based on the combined positive and 
negative staining patterns for CD45RA/CD57/CD27/CD28 monoclonal antibodies within each CCR7 
compartment. Each CCR7 staining compartment was subdivided into CD45RA
–
 and CD45RA
+
 subsets, and each 
CD45RA subpopulation was then further subdivided into CD57
–
 and CD57
+
 T cells. Final delineation of 
subpopulations was defined by expression of CD27 and CD28 on T cells in each subpopulation. T
CM
 = central 
memory T cell, T
EM
 = effector memory T cells, T
EFF
 = effector T cells, T
EMRA
 = effector memory T cell re-
expressing CD45RA, and TRVE = resting vigilant effector T cells ***p<0.001, **p<0.01, *p<0.05  
3.4 CCR7
–
 re-directed T cells secreted IFN and IL-2 
Since re-directed T cells displayed a CCR7
–
 phenotype which suggested the presence of 
effector and effector memory T cells, it was further hypothesized that re-stimulation of the 
CCR7
–
 subset would result in the release of distinct cytokines. Therefore, re-directed T cells 
from six consecutive donors were activated with the anti-idiotypic (AI) Fab or control Fab, 
respectively. Activation of the CCR7
–
 hIgG
+
 subset resulted in antigen-specific release of 
IFN or IL-2 or the combination of both (figure 3-6 A and 3-6 B). Given the low cell count of 
CCR7
+
 hIgG
+
 T cells, no conclusion of their cytokine profile could be drawn.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7: Intracellular analyses of re-
directed T cells harboring the T1-
CD28/CD3CAR were conducted by flow 
cytometry three days after transduction. 
Re-directed T cells were stimulated for 12 h 
with the anti-idiotypic antibody (A) and 
control Fab (B). hIgG
+
 cells were gated in 
CCR7
–
 and CCR7
+
 cells. Both CCR7 
compartments were arrayed in IL-2 vs. IFN 
dot-plots. Nine consecutive re-stimulations 
from individual donors were summarized in 
C. ***p<0.001, **p<0.01, *p<0.05, ns = not 
significant 
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3.5 CCR7+ hIgG+ T cells down-regulated CCR7 and expressed  
IL-2 after re-stimulation 
Re-directed central memory T cells were detected by employing multi-color flow cytometry 
analysis (figure 3-6). Their antigen-specific functionality was tested and it was speculated 
that activation of re-directed CCR7
+
 T cells resulted in differentiation towards CCR7
–
 TEFF and 
TEM cells. Therefore, re-directed CCR7
+
 T cells were sorted and re-stimulated with anti-
idiotypic Fab AI or control Fab. Activation of the re-directed CCR7
+
 T cell population resulted 
in a significant, antigen-specific reduction of hIgG
+
 CCR7
+
 T cells and a significant increase 
of hIgG
+
 CCR7
–
 T cells. In contrast, sorted re-directed CCR7
–
 T cells showed no significant 
change of CCR7 expression (figure 3-8 A) suggesting no phenotypical change after 
activation. To demonstrate antigen-specific secretion of the memory signature cytokine IL-2, 
re-directed CCR7
+
 T cells were sorted and re-stimulated. Re-directed CCR7
+
 T cells 
demonstrated antigen-specific release of IL-2 and only low levels of IFN. In contrast, sorted 
re-directed CCR7
–
 T cells produced primarily IFN and additionally IL-2. However, IL-2 
secretion was significantly lower compared to CCR7
+
 sorted re-directed T cells (figure 3-8 B). 
 
Figure 3-8: Sorting of hIgG
+
CCR7
+
 and hIgG
+
CCR7
–
 T cells and subsequent re-stimulation with anti-
idiotypic antibody and control Fab. 
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CCR7 expression was re-assessed 10 days after re-stimulation in the presence of 50 ng/ml IL-15 for both, 
hIgG
+
CCR7
+
 and hIgG
+
CCR7
–
 sorted T cells in six individual experiments (A). IL-2 and IFN secretion from 
hIgG
+
CCR7
+
 and hIgG
+
CCR7
–
 sorted cells was measured by ELISA after 24 h of re-stimulation (B). ***p<0.001, 
**p<0.01, ns = not significant 
3.6 Re-directed T cells protected against tumor outgrowth in a 
multiple myeloma xenograft model 
The above findings indicated antigen-specific functionality of NY-ESO-1 specific re-directed T 
cells in vitro. A xenograft model in NOD/SCID/c
null (NSG) mice was established to test 
whether these re-directed T cells were protective against a HLA-A*02:01/ NY-ESO-1 positive 
human myeloma cell line (U266).  
3.6.1 Intravenous injection of U266 cells established a human multiple 
myeloma model in NOD/SCID/c
null (NSG) mice 
To establish a multiple myeloma xenograft model, NOD/SCID/c
null mice were irradiated and 
subsequently intravenously or intraperitoneally injected with different doses of U266 cells to 
allow for tumor growth in the bone marrow or in the peritoneal cavity, respectively. U266 cells 
secrete the paraprotein hIgE which was measured in serum samples of animals and was 
used as a surrogate marker for tumor burden. hIgE kinetics of intravenously injected mice 
with the doses 6*106, 107 and 2*107 varied only marginally. Between day 25 and day 33 after 
i.v. injection, all mice (9/9) had measureable hIgE proteins in their blood which was followed 
by a rapid increase of hIgE levels over time. 2/3 mice i.p. injected with 2*107 U266 cells 
showed first measurable hIgE levels at day 19, 1/3 mice only developed measureable hIgE 
levels 75 days after injection (figure 3-9).  
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Figure 3-9: Xenograft model of injected 
U226 HLA-A*02:01/NY-ESO-1 positive 
myeloma cells. 
After injection of different doses of U266 and 
different routes the concentration of secreted 
human IgE was measured by ELISA.  
2/3 i.p. injected mice developed a solid tumor at the peritoneum of the size 7x8 mm at day 33 
(figure 3-10 A). Mice showed no symptoms. No U266 cells were found in the blood or the 
bone marrow (data not shown). Mice i.v. injected with U266 cells developed with time (after 
day 65) disease symptoms, including ruffled fur, hunched posture, failure to eat and drink 
and hind limb paralysis. Mice with severe hind limb paralysis were X-rayed to detect 
osteolytic lesions (figure 3-10 B).  
 
Figure 3-10: Growth of i.p. injected U266 cells at day 39 (A) and X-ray analysis of i.v. injected mice at day 
69 (B).  
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Growth of a 7x8 mm sized tumor (red circle) was seen at the peritoneum (2/3 mice) after i.p. injection of 2*10
7
 
U266 cells (A). X-ray of a mouse which suffered from severe hind leg paralysis indicated osteolytic lesions (red 
arrow, B). 
Staining and subsequent flow cytometry analysis of HLA class I molecules were used to 
detect U266 cells. Bone marrow analysis of mice exhibiting severe hind limb paralysis 
showed a high percentage of HLA class I positive cells. This was found in the bone marrow 
of the spine as well as femur and tibia. In contrast, no HLA class I staining was detected in 
the blood (figure 3-11).  
 
Figure 3-11: Flow cytometry analyses of the blood and bone marrow of U266 i.v. injected mice at day 69.  
The grey filled area shows the isotype control, the solid black line depicts HLA class I staining which was used to 
recognize U266 cells. As positive control served in vitro cultured U266 cells.  
Furthermore, histopathological analyses confirmed massive U266 infiltration of the bone 
marrow of the femur (figure 3-12 A and B). Additionally, U266 cells invaded into the spinal 
cavity (figure 3-12 C and D). On day 69 after U266 injection, multiple myeloma cells were 
replacing the bone marrow environment and areas with normal residual hematopoiesis could 
be rarely detected (figure 3-12 E and F). 
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Figure 3-12: H&E stainings of femur (A, B) and spine (C, D) of NSG mice injected with 10
7
 U266 cells at 
day 69 after injection. 
Extensive accumulation of U266 cells was found in the femur of mice (A, B). U266 cells grew in the spinal cord 
(C) and formed nests (D, arrow). The junction between normal hematopoiesis and U266 outgrowth was shown in 
E and normal residual hematopoiesis (both bone marrow of the tibia) in F. 
3.6.2 Protective capacity of re-directed T cells against multiple myeloma 
outgrowth 
To investigate the protective capacity of re-directed T cells, 106 re-directed CD8+ T cells 
specific for NY-ESO-1157-165/HLA-A*02:01 complexes (T1-CD28/CD3) or for CEA 
(BW431/26-CD28/CD3) were intravenously injected 5 days after U266 transplantation. One 
group did not receive any treatment. Human IgE serum levels were measured by ELISA as a 
surrogate marker for tumor growth. No difference in hIgE levels between the three groups 
was observed (figure 3-13).  
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Figure 3-13: Xenograft model of i.v. 
injected U266 cells treated with re-directed 
T cells or left untreated.  
Re-directed T cells (10
6
 NY-ESO-1 specific 
re-directed T cells (●, red), 2*10
6
 CEA specific 
T cells (♦, green)) were injected at day 5 after 
U266 implantation or left untreated (■, black). 
The transduction efficiency of NY-ESO-1 
specific re-directed T cells was 50 %. As 
specificity control served CEA-specific re-
directed T cells.  
The treatment schedule was changed and the numbers of injected re-directed T cells were 
raised as no delay in tumor outgrowth was observed when injected with 106 NY-ESO-1 
specific T cells. 107 re-directed CD8
+
 T cells were injected 5 days after tumor transplantation. 
T1-CD28/CD3 re-directed T cells protected mice against tumor outgrowth which was 
assessed by the surrogate marker hIgE (figure 3-14).  
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Figure 3-14: Xenograft model of 
intravenously injected U226 HLA-
A*02:01/NY-ESO-1 positive myeloma 
cells. 
Mice were treated with 10
7
 NY-ESO-1 
specific (●, red) or 2*10
7
 CEA specific (♦, 
green) or no (■, black) re-directed T cells. 
The transduction efficiency for re-directed 
NY-ESO-1 specific T cells was 50 %. 
Human IgE levels were significantly different at various time points between the non-treated 
group and the T1-CD28/CD3 treated group as calculated by Mann-Whitney U-test indicating 
protection against tumor outgrowth in the bone marrow (table 3-1).  
 
day P-value (Mann-Whitney U-test) 
25 0.000751 
30 0.000064 
35 0.000064 
40 0.000300 
45 0.000300 
50 0.000579 
55 0.006736 
66 0.063603 
 
 
 
 
 
 
 
Table 3-1: Mann-Whitney U-test showed 
statistical significant differences between 
untreated and T1-CD28/CD3 treated group up to 
day 55. 
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Mice treated with BW431/26-CD28/CD3 CAR positive T cells developed measurable IgE 
levels but succumbed early after CAR T cell injection. Macroscopic pictures showed massive 
destruction of the GIT (figure 3-15 A). However, microscopic H&E stainings of the lamina 
propria and the villi failed to show lymphocyte infiltrates (figure 3-15 B). 
 
Figure 3-15: Macroscopic (A) and microscopic H&E (B, C) analyses of mice after injection of CEA-specific 
re-directed T cells.  
Panel A depicts the atypical GIT of an injected mouse and panels B and are H&E stainings of the intestinal tract. 
Mice were analyzed for hIgG
+
 cells at various time points after transfer. Analysis of peripheral 
blood mononuclear cells revealed persistence of hIgG
+
 CD8
+
 T cells in 4 out of 10 mice until 
day 30 after adoptive transfer (figure 3-16). Re-directed T cells harbored an exclusive CCR7
–
 
phenotype and comprised between 6.5 and 1.4 % of total CD8
+
 T cells. 
 
 
 
 
 
Figure 3-16: Re-directed T cells were found up 
to 30 days after transfer in the peripheral 
blood of different mice.  
Representative dot plots of four individual mice 
are shown. Plots are shown for pre-gated human 
CD3
+
CD8
+
 cells.  
After day thirty, 90% of the mice started to develop graft versus host disease (GvHD) like 
symptoms. They lost weight, displayed limited mobility, the fur was ruffled and the general 
appearance of mice was disrupted. The GIT track of mice with GvHD like symptoms 
appeared to be black (figure 3-17 A) and H&E sections of lung tissue revealed mixed 
inflammatory lymphocyte infiltrates with a high proliferation rate (figure 3-17 B). Liver 
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sections showed massive lymphocyte infiltration and proliferation. Extensive degradation of 
collagen and fibronectin as well as the destruction of hepatocytes could be observed in liver 
tissue (figure 3-17 C). However, the GIT was deprived of lymphocyte infiltrates and appeared 
to be normal (figure 3-17 D).  
 
Figure 3-17: Macroscopic (A) and microscopic H&E (B-D) analyses of mice displaying GvHD-like 
symptoms.  
Panel A shows the intestinal tract which appeared to be black. The H&E section of lung tissue (B) displayed 
mixed inflammatory lymphocyte infiltrates which had a high proliferative index. A high expansion of lymphocytes 
was seen in the liver section (C). Extensive fibrosis and the destruction of hepatocytes suggested GvHD-like 
disease. The small bowel (D) section was not infiltrated by lymphocytes and appeared normal. 
Flow cytometry analyses of spleen, bone marrow and blood revealed a HLA class I/CD3 
double positive population which was negative for hIgG (figure 3-18). The bone marrow and 
the spleen harbored up to 92 % and 65 % of CD3
+
 cells, respectively. 
 
Figure 3-18: Flow cytometry analyses of mice displaying GvHD-like disease.  
65 % of splenocytes and 92 % of bone marrow associated cells were CD3 and HLA class I double positive. This 
population also expressed CD8 but was negative for hIgG. In the blood, an extensive amount of CD8
+
 cells was 
found which were hIgG
–
. 
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4 Discussion 
The concept of adoptive T cell transfer is gaining significant attention as phase I/II clinical 
trials (June, 2007) have demonstrated clinical responses (Rosenberg and Dudley, 2009) in 
patients with cancer of advanced stage. Most recently, the successful treatment of patients 
with chronic lymphoid leukemia has been reported (Porter et al., 2011). This project 
demonstrated antigen-specific functionality of HLA-A*02:01/ NY-ESO-1157-165 re-directed T 
cells in vitro. Transduced T cells consisted of multiple subpopulations. The majority of CD8
+
 
re-directed T cells displayed an effector-memory phenotype. Interestingly, a subset of T cells 
with central memory phenotype was also antigen-specific. Furthermore, the data suggested 
a protective effect of adoptively transferred NY-ESO-1 specific re-directed T cells against 
neoplastic plasma cells in a xenograft model. 
First and second generation CAR contructs were generated recognizing the HLA-A*02:01/ 
NY-ESO-1157-165 complex and were used to retrovirally transduce CD8
+
 T cells. The 
intracellular moiety consisted either of a CD3 only or a combined CD28/CD3 signaling 
domain. Both constructs achieved similar transduction efficacies and were able to recognize 
the target antigen in a specific manner (figure 3-3 and 3-4). However, functional analyses of 
the CARs revealed that additional CD28 signaling resulted in significantly increased target 
cell lysis and IFN release. The data are in line with data from Willemsen et al. (2005), who 
previously reported that activation of a HLA class I restricted CAR resulted in an increased 
lytic capability and cytokine secretion. In contrast, classic CARs that bind to cell surface 
molecules do not display elevated cytolysis but show increased IFN release (Hombach et 
al., 2001; Pinthus et al., 2003). Furthermore, it was demonstrated that cytolysis and cytokine 
release are highly antigen specific events. CARs did not recognize the HLA-A*02:01/NY-
ESO-1157-167 complex which only differs by two additional amino acids. This is in contrast to 
the previous report of an affinity maturated MAGE-A1/HLA class I restricted second 
generation CAR construct. Testing of cells transduced with this construct resulted in 
unspecific cytolysis and IFN release of HLA class I target cells which did not express the 
MAGE-A1 peptide (Willemsen et al., 2005). HLA-A*02:01 positive multiple myeloma cells 
with endogenous NY-ESO-1 expression were lysed at a target: effector ratio of 4:1. Cell lines 
stable transfected with the NY-ESO-1157-165 peptide already showed antigen specific lysis at a 
target: effector ratio of 1:1. This observation can be attributed to the lower expression of 
antigen in endogenously NY-ESO-1 expressing cells. 
Additionally, flow cytometry was employed to delineate subpopulations of CAR transduced T 
cells. Since a physiological and effective immune response results in multiple functionally 
different subsets of T cells including memory and effector cells (Sallusto et al., 2004), it is 
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important to have a similar composition of re-directed T cell subsets. Such multi-functionality 
is of special interest when immune therapy is intended to control minimal tumor burden over 
time. CD8
+
 T cells can be classified in naïve, effector T cells (TEFF) and memory T cells (TM) 
depending on their antigen-experience, activation state, longevity and proliferation capacity 
(Sallusto et al., 2004). Even if the lineage development of CD8
+
 TM cells is not finally 
understood, different subpopulations of CD8
+
 T cells are phenotypically and functionally 
characterized. Central memory T cells (TCM) are phenotypically described as 
CCR7
+
CD45RA
–
CD57
–
CD27
+
CD28
+
 whereas effector memory T cells (TEM) have the CCR7
–
CD45RA
–
CD57
–
CD27
+
CD28
+/– phenotype (van Baarle et al., 2002). 
Circulating or tissue-resident CD8
+
 TEM display immediate effector function upon antigen 
recognition. TCM reside in the T cell areas of lymphoid tissues where they can mount a rapid 
recall response after recognizing their cognate antigen presented by dendritic cells (Wherry 
et al., 2003). Multiple effector and memory populations within the CAR re-directed T cells 
were phenotypically identified based on consensus models of 3 to 7 marker analyses 
(Ahmed et al., 2009; Klebanoff et al., 2006; Kern et al., 1999; Geginat et al., 2003; Walker et 
al., 2008). Primarily early and late effector memory phenotypes were found in the re-directed 
T cells (CCR7
–
CD45RA
–
CD57
–
CD27
+
CD28
+
 and CCR7
–
CD45RA
–
CD57
–
CD27
+
CD28
–
, 
respectively) and small populations of fully differentiated effector T cells (CCR7
–
CD45RA
+
CD57
+
CD27
+/–CD28
–
). This was expected as the re-directed T cell populations 
showed immediate IFN secretion and cytotoxicity. Since the majority of re-directed T cells 
had a late and early TEM phenotype, the immediate antigen-specific response in vitro and the 
protection in vivo were presumably mediated by TEM cells. Unexpectedly, a minor population 
of central memory re-directed T cells (CCR7
+
CD45RA
–
CD57
–
CD27
+
CD28
+
) was detected. 
Barber et al. (2008) showed an early effector differentiation phenotype of chimeric NKG2D 
expressing CD8
+
 T cells after 10 days of culture. Neeson et al. (2010) reported that LeY re-
directed T cells mainly displayed effector and central memory phenotypes by the end of the 
transduction. These differences may result from the different T cell activation and retroviral 
transduction protocols. In both publications, T cells were stimulated by anti-CD3 (OKT3) and 
IL-2 for 3 days and subsequently retrovirally transduced for 5 or 7 days, respectively. In 
contrast, in this thesis T cells were activated with anti-CD3, anti-CD28 monoclonal antibodies 
and IL-2 for two days and the transduction lasted for 4 days via 293T co-culture. Neeson et 
al. analyzed a second generation CAR construct harboring a CD28/CD3 domain and Barber 
et al. a primary construct expressing the CD3 chain only. Here, analysis of 11 different 
donors revealed only slight differences in the phenotypical composition of re-directed T cells 
expressing different signaling domains. Most notably, re-directed T cells without CD28 
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signaling displayed higher amounts of early TEM, less late TEM cells and more TEMRA cells 
compared to CD28/CD3 re-directed T cells.  
A minor population of central memory re-directed T cells (CCR7
+
CD45RA
–
CD57
–
CD27
+
CD28
+
) was detected comprising 3 - 8 % of the re-directed T cell pool. These cells are 
of special interest as they might be able to generate functional effector T cells after antigen 
re-encounter and thus be able to control residual dormant tumor cells. Kalos et al. (2011) 
reported the infusion of CD19-41BB CAR transduced CD3+CD28+ T cells from three 
patients with advanced chronic lymphocytic leukemia. 56 days after adoptive T cell transfer, 
the CAR+ CD8+ T cell compartment displayed primarily an effector phenotype (CCR7
–
CD27
–
CD28
–
). However, on day 169 a population evolved with features of a central memory 
phenotype (CCR7+CD27+CD28+CD57
–
). These engineered T cells expanded >1000 fold in 
patients and travelled to the bone marrow, resulting in a complete remission in two of three 
patients (Kalos et al., 2011). Furthermore, alternative approaches to generate a functional 
and persisting CAR positive memory pool are currently elucidated. Pule et al. (2008) 
described an approach to express CARs on CTLs specific for viral antigens. These CTLs 
were supposed to display a memory phenotype and to receive superior co-stimulation in vivo 
by engaging with APCs through their native TCR. A first generation CAR was generated 
recognizing the GD2 antigen expressed by neuroblastoma tumor cells. CAR positive CTLs 
survived on a higher level over the 6-week study period compared to bulk transduced T cells 
(Pule et al., 2008). However, after the 6-week period CAR positive CTLs became 
undetectable. Nevertheless, the follow-up study showed three out of eleven patients with 
active disease achieved complete remission and persistence of CAR CTLs was concordant 
with co-infusion of CD4+ T cells and CD45RO+CD62L+ central memory cells (Louis et al., 
2012). Terakura et al. (2012) reported a method to generate second generation CAR specific 
CD8+ T cells derived from virus-specific central memory cells. An elaborate method was 
employed to obtain virus-specific T cells from CD45RA
–
CD62L+CD8+ central memory T cells 
from donor blood. These cells were able to expand in vitro and form a large pool of CAR 
positive effector T cells exhibiting target-antigen specific effector functions in vitro (Terakura 
et al., 2012). 
Re-directed T cells with CD28/CD3 signaling domain were functionally superior when 
compared to ones with the CD3 domain only. Therefore, T cells harboring the CD28 
signaling domain were analyzed in more detail to investigate functional differences of the 
phenotypically delineated T cell subpopulations in vitro. Since phenotypical analyses 
suggested antigen-specific functionality was mainly mediated by TEM, the cytokine profile of 
the CCR7
–
 re-directed subpopulation was studied. Re-stimulation of CCR7
–
 re-directed T 
cells resulted in the simultaneous release of IFN and IL-2 in a portion of transduced T cells. 
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This cytokine profile supports our phenotypical data. Early effector memory T cells produce 
IFN and IL-2 after antigen recognition (Cui and Kaech, 2010), which represent a substantial 
subset of the CCR7
–
 re-directed T cells. Furthermore, sorting and subsequent analysis of 
cytokine secretion of CCR7
+
 and CCR7
–
 re-directed T cells revealed that hIgG
+ 
CCR7
+
 T 
cells released significantly more IL-2 than CCR7
–
 re-directed T cells. CCR7
– 
CAR
+
 T cells 
released more IFN than CCR7
+ 
CAR
+
 T cells, and they also secreted IL-2. This is in 
accordance with previously reported data which demonstrated that CD45RA
– 
CCR7
–
 TEM 
cells secrete high amounts of IFN and, to a lesser extent, IL-2 whereas CD45RA
– 
CCR7
+
 T 
cells released mainly IL-2, the signature cytokine of central memory cells (Sallusto et al., 
1999).  
Although memory lineage development is still controversial (Ahmed et al., 2009), data 
suggest that secondary activation of TCM results in strong proliferation and differentiation into 
TEFF (Sallusto et al., 1999). In our model, re-stimulation of CCR7
+
 re-directed T cells led to 
down-regulation of CCR7 supporting differentiation of central memory into effector T cells. 
To explore the in vivo functionality of re-directed T cells, a xenograft model was chosen 
which mimics the pathology of human multiple myeloma. 
Multiple Myeloma (MM) is characterized by neoplastic transformed plasma cells in the bone 
marrow (Palumbo and Anderson et al., 2011) and, in general, considered to be an incurable 
disease. It accounts for about 1 % of all cancers and more than 10 % of blood borne 
malignancies. Multiple myeloma is an exclusive post-germinal center cancer, which is 
verified by the fact that throughout the clinical course the Ig gene sequences are somatically 
hypermutated and remain constant (Bakkus et al., 1992; Sahota et al., 1997). In recent 
years, many therapeutic advances have been made to treat multiple myeloma patients 
including combined chemotherapy and hematopoietic stem cell transfer but most patients 
cannot expect long-term remission. This is due to drug-resistant or minimal residual disease 
(Hideshima and Anderson et al., 2002). Additionally, the lack of in vivo systems which mimic 
the growth of human multiple myeloma cells and the development of clinical manifestations 
hampered further development of new therapeutic strategies. New approaches have to be 
developed for eradication or control of residual malignant plasma cell burden (Szmania et al., 
2006). Therefore, a xenograft multiple myeloma model was established to evaluate the 
functionality of HLA-A*02:01/ NY-ESO-1157-165 re-directed T cells in vivo. 
Immunodeficient mice derived from the inbred mouse strain NOD/ShiLtJ which also lack the 
interleukin-2 receptor  chain (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; NOD scid gamma; NSG) 
served as animal model for human multiple myeloma. NSG mice lack B and T cells and show 
several defects of innate immunity, namely impaired dendritic cell function (no production of 
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IFN), a complete lack of NK cells, impaired production of interleukin-1 by macrophages, 
and an absent hemolytic complement system (Shultz et al., 1995). 
Before establishment of the NSG mouse strain, in vivo human multiple myeloma models 
have been carried out with SCID and NOD/SCID mice. However, simple intravenous 
injection of multiple myeloma cells did not lead to engraftment (Yaccoby et al., 1998; 
Yaccoby and Epstein, 1999; Pilarski et al., 2000; Urashima et al., 1997). Miyakawa et al. 
(2003) established engraftment of the human multiple myeloma cell line U266 in NOG mice 
(also NOD scid IL2R deficient mice) by sublethal irradiation with 2.4 Gy followed by 
intravenous injection of 2x106 U266 cells. All mice developed disease symptoms such as 
hunched posture, rough fur, failure to eat and drink and, finally, severe hind leg paralysis 
around 6 weeks after tumor cell injection. Three different doses of U266 cells were injected 
i.v. into NSG mice after 2.4 Gy irradiation (figure 3-9). All mice developed disease symptoms 
and severe hind leg paralysis between week 6 and 10. Histological and flow analyses 
revealed engraftment of U266 cells only in the bone marrow and not in the blood (figure 3-11, 
3-11) which is in accordance with Miyakawa et al. (2003). U266 cells specifically invaded the 
murine bone marrow which allowed the development of clinical manifestations seen in 
myeloma patients (Roodman 1997; Dhodapkar et al., 1998). Furthermore, on X-ray films the 
formation of osteolytic lesions of the trabecular bones near the spine were detected (figure 3-
10 B). Histological studies of U266 transplanted NOG mice showed osteolytic lesions of 
cortical bones and loss of trabecular bones in the sternum and spine (Miyakawa et al., 2003). 
Additionally, U266 tumor growth was confirmed by measuring hIgE serum levels as 
surrogate marker. Continuous hIgE production was observed which increased over time 
(figure 3-9), likely due to proliferation and expansion of U266 cells in the murine bone 
marrow.  
106 re-directed T cells were injected in the tail vein five days after i.v. transplantation of 107 
U266 cells. No delay in tumor growth was observed between different treatment groups. 
Therefore, a new experimental outline with injection of 107 re-directed T cells was set. 9/10 
mice treated with 107 T1-CD28/CD3 CAR positive T cells did not develop any detectable 
hIgE levels compared to the untreated control group. The statistical significance was 
confirmed applying a Mann-Whitney U-test up to day 55. Peinert et al. (2010) injected 
subcutaneously into NOD/SCID mice a deposit of RPMI 8226-13 cells, a LeY positive MM cell 
line. One day later they injected 107 retrovirally transduced anti-LeY-scFv-CD28/CD3 T cells. 
Peinert et al. (2010) reported a delay of plasmacytomas in the specifically treated group, 
resulting in an improved overall survival. 
Mice treated with BW431/26-CD28/CD3 CAR positive T cells succumbed between day 7 
and 16. However, these mice developed measurable hIgE levels at early time points 
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indicating the specificity of the re-directed T cells in vivo (figure 3-14) as seen in vitro (figure 
3-4). This early death of mice and restriction to the CEA re-directed T cells injected group 
suggested an on-/off-target effect of the injected CEA-specific T cells than the induction of a 
xeno-GvHD reaction. Murine analogues of human CEA share up to 100 % of its sequence. 
They are glycoproteins expressed in the GIT of human and mice. Macroscopic analyses 
showed massive destruction of the GIT indicating on-target specificity of CEA specific re-
directed T cells in the murine gut (figure 3-15). 
Furthermore, NY-ESO-1 CAR transduced T cells were present in 40 % (4/10) of peripheral 
blood samples of treated animals after 30 days of adoptive transfer. Interestingly, hIgG 
expression did not coincide with CCR7 expression, indicating an effector phenotype of re-
directed T cells. This finding is consistent with flow cytometry data showing mainly CCR7
–
 
phenotype of re-directed T cells (figure 3-5). Additionally, down-regulation of the CCR7 
receptor was observed after antigen re-stimulation in vitro (figure 3-8). Zhao et al. also 
reported a gradual loss of CAR expression but was able to prolong persistence of re-directed 
T cells by adding a 4-1BB cytoplasmic domain to the CD28/CD3 moiety in vivo (Zhao et al., 
2009). Most recently, the formation of central memory cells was detected in re-directed T 
cells with CAR consisting of a 4-1BB cytoplasmic domain and CD3 signaling domain after 
the transfer into patients with chronic lymphoid leukemia (Kalos et al., 2011). 
After day 30, 90 % of mice injected with NY-ESO-1 specific T cells started to develop 
symptoms of xeno-GvHD, including weight loss, ruffled fur and limited mobility (Gregoire-
Gauthier et al., 2011). It was speculated that irradiation of NSG mice carrying a Prkdc gene 
mutation led to irreparable tissue damage (Kirchgessner et al., 1995). This damaged and 
presumably inflamed tissue was then infiltrated by xeno-reactive T cells causing GvHD. Ito et 
al., (2009) reported death of NOG mice irradiated with 2.5 Gy and i.v. injected with 107 
hPBMCs after day 14. This difference in time delay may be due to i.v. injection of human 
CD8
+
 T cells only compared to whole hPBMCs. Further histological analyses (figure 3-17) 
revealed massive lymphocyte infiltration in lung and liver which is in accordance to Ito et al. 
(2009). Interestingly, the small bowel appeared microscopically to be physiological normal 
though the GIT was colored black which might be due to inner bleedings. In accordance, Rijn 
et al. (2003) and Ito et al. (2009) observed heavy lymphocyte infiltrations in lung and liver but 
not in the gut after induction of xeno-GvHD. Flow cytometry analyses of bone marrow, spleen 
and blood confirmed high levels of human CD8
+
 T cells (figure 3-18). Ito et al., (2009) 
reported high ratios of human CD45
+
 cells in spleen and blood but lower ratios in bone 
marrow (20 %-40 %). Around 90 % of cells found in the bone marrow stained for human 
CD8
+
. This might be due to the initial re-direction of CAR transduced CD8
+
 T cells towards 
U266 cells which homed to the murine bone marrow. 
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In summary, it was demonstrated that NY-ESO-1157-165/HLA-A*02:01 re-directed T cells with 
a high affinity CAR exhibit strong effector functions without loss of specificity when CD28 
signaling is provided through the CAR. Re-directed effector and central memory T cells were 
phenotypically identified which displayed characteristic antigen-specific functionality in vitro. 
Furthermore, CAR re-directed T cells were able to prevent tumor outgrowth of multiple 
myeloma in a xenograft model, which mimicked the development and pathogenesis of 
human MM. The results are a rational for the potential clinical use of NY-ESO-1157-165/HLA-
A*02:01 re-directed T cells for consolidation therapy in multiple myeloma. CCR7
+
 re-directed 
T cells are of special interest for further development of adoptive T cell therapy to not only 
resolve existing primary tumors but also to keep residual or dormant tumor cells under 
control over long time. Approaches have to be developed to exploit the full therapeutic and 
protective potential of these already existing central memory T cells in the retrovirally 
transduced T cell population.  
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